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Abstract
Neuropsychiatric diseases represent a major public health burden worldwide; due to gaps in our
understanding of the pathogenic mechanisms of disease, approximately 30% of patients are refractory to
treatment. Activation of neuroinflammatory signaling cascades has shown promise as a contributing factor for
disease development. This hypothesis is driven in part by an intriguing overlap of symptoms in patients with
neuropsychiatric and immunological disorders. Patients with depression, bipolar disorder, schizophrenia, and
autism commonly present with immune dysfunction, while patients with multiple sclerosis, lupus, and
rheumatoid arthritis often experience severe mood disturbances. Diversity in presentation of symptoms,
however, has posed a research challenge to our mechanistic understanding of this link. In contrast to the
complexity of modeling specific diseases, altered sensitivity to stress is a well-documented vulnerability
marker across neuropsychiatric disorders. Of relevance to clinical advancement, aspects of stress behavior and
physiology can be modeled and measured in animals, where core components of the stress axis are conserved
in humans and rodents. Thus, we performed an examination of the neuroinflammatory regulation of stress
behavior and physiology. Using a genetic model of stress sensitivity, we report the discovery that anti-
inflammatory treatment ameliorates hypothalamic-pituitary-adrenal axis dysregulation, identifying the dorsal
raphe (DR) as a locus of heightened responsivity. We then demonstrated sex differences in this brain region in
response to the stress neuropeptide, corticotropin-releasing factor, suggesting that differences in its
responsivity may underlie sex differences in vulnerability to stress-related disorders. Finally, we used a
transgenic approach to show that neuroinflammation localized specifically to the DR results in dysregulated
stress behavior and physiology through interactions with the serotonergic neurotransmitter system. Overall,
this work demonstrates that hyper- or hypo-function of the DR, based on genetic susceptibility, sex, or
neuroinflammatory insult, can result in altered stress physiology and behavior. Though the DR has previously
been identified as a potential locus of dysregulation, here we establish the specific, mechanistic link between
risk factors for stress-related disorders. We present evidence of quantitative changes to this brain region and its
functional output, and demonstrate that differences in responsivity of the DR may underlie vulnerability to
stress-related disorders.
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ABSTRACT 
 
NEUROINFLAMMATORY REGULATION OF  
STRESS BEHAVIOR AND PHYSIOLOGY  
 
Alexis Rose Howerton 
Tracy L. Bale 
 
Neuropsychiatric diseases represent a major public health burden worldwide; due 
to gaps in our understanding of the pathogenic mechanisms of disease, approximately 
30% of patients are refractory to treatment. Activation of neuroinflammatory signaling 
cascades has shown promise as a contributing factor for disease development. This 
hypothesis is driven in part by an intriguing overlap of symptoms in patients with 
neuropsychiatric and immunological disorders. Patients with depression, bipolar disorder, 
schizophrenia, and autism commonly present with immune dysfunction, while patients 
with multiple sclerosis, lupus, and rheumatoid arthritis often experience severe mood 
disturbances. Diversity in presentation of symptoms, however, has posed a research 
challenge to our mechanistic understanding of this link.  
In contrast to the complexity of modeling specific diseases, altered sensitivity to 
stress is a well-documented vulnerability marker across neuropsychiatric disorders. Of 
relevance to clinical advancement, aspects of stress behavior and physiology can be 
modeled and measured in animals, where core components of the stress axis are 
conserved in humans and rodents.  
Thus, we performed an examination of the neuroinflammatory regulation of stress 
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behavior and physiology. Using a genetic model of stress sensitivity, we report the 
discovery that anti-inflammatory treatment ameliorates hypothalamic-pituitary-adrenal 
axis dysregulation, identifying the dorsal raphe (DR) as a locus of heightened 
responsivity. We then demonstrated sex differences in this brain region in response to the 
stress neuropeptide, corticotropin-releasing factor, suggesting that differences in its 
responsivity may underlie sex differences in vulnerability to stress-related disorders. 
Finally, we used a transgenic approach to show that neuroinflammation localized 
specifically to the DR results in dysregulated stress behavior and physiology through 
interactions with the serotonergic neurotransmitter system. 
Overall, this work demonstrates that hyper- or hypo-function of the DR, based on 
genetic susceptibility, sex, or neuroinflammatory insult, can result in altered stress 
physiology and behavior. Though the DR has previously been identified as a potential 
locus of dysregulation, here we establish the specific, mechanistic link between risk 
factors for stress-related disorders. We present evidence of quantitative changes to this 
brain region and its functional output, and demonstrate that differences in responsivity of 
the DR may underlie vulnerability to stress-related disorders. 
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CHAPTER 1: INTRODUCTION 
 
The goal of this dissertation is to understand the contribution of 
neuroinflammation to the regulation of stress related behavior and physiology, with the 
hope of providing insight into specific targetable, pathogenic mechanisms of stress-
related disease. In this dissertation I focus on the bidirectional relationship between stress 
exposure/coping behavior, and neuroinflammation, both brain-wide and in potentially 
susceptible brain regions. I have specifically focused on the contribution of the 
serotonergic dorsal raphe nucleus (DR) as a locus of vulnerability. Using a genetic model 
of stress sensitivity, I report the discovery that anti-inflammatory treatment ameliorates 
hypothalamic-pituitary-adrenal (HPA) stress axis dysregulation. I then characterize sex 
differences in the DR response to the stress neuropeptide, corticotropin-releasing factor 
(CRF), demonstrating that sex differences in responsivity may contribute to differences in 
vulnerability to stress-related disorders. Finally, I use a transgenic approach to show that 
neuroinflammation localized specifically to the DR results in dysregulated stress behavior 
and physiology through interactions with the serotonergic neurotransmitter system. This 
work has helped gained insight into the potential mechanism underlying the clinical 
overlap of neuroimmune and neuropsychiatric symptomology. 
 The following introductory chapter describes the challenges associated with the 
advancement of research in neuropsychiatric disease, providing background of how, by 
utilizing different models of vulnerability, one might learn about this family of stress-
related disorders. This includes a general description of psychiatric disease symptom 
presentation, background on the stress response, and a primer on the neuroimmune 
system. As the majority of this dissertation describes experiments examining the specific 
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contribution of the serotonergic DR, I provide extensive background on the known role 
for this brain region and neurotransmitter system to respond to, and affect, stress related 
behavior and physiology. The introduction then focuses on how the relationship between 
these factors has been studied in humans with disease and in animal models. Finally, I 
present an overview of the goals of this dissertation, and the potential implications of the 
findings presented herein. 
 
Neuropsychiatric disease: a major unmet medical need 
Neuropsychiatric diseases represent a major public health burden worldwide, 
accounting for 13% of the global burden of disease (Collins et al., 2011). In the United 
States, it is estimated that 26.2% of adults suffer from a diagnosable mental disorder 
every year (Kessler et al., 2005b; Wang et al., 2005).  
The complex clinical manifestations of neuropsychiatric disorders generally fall 
in an overlap of domains, where examples include: sadness, confused thinking or reduced 
ability to concentrate, excessive fears or worries, extreme mood changes of highs and 
lows, withdrawal from friends and activities, significant tiredness or low energy, 
problems sleeping, detachment from reality (delusions), paranoia or hallucinations, 
extreme feelings of guilt, alcohol or drug abuse, major changes in eating habits, changes 
in sex drive, excessive anger or hostility or violence, suicidal thinking, and an inability to 
cope with daily problems or stress (MayoClinic, 2012). However, even within a 
particular diagnosis, illnesses vary with respect to symptom number, type, intensity, and 
duration. 
This heterogeneity in disease development, presentation, and trajectory is likely 
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due to the complex nature of risk factors, which include environment, genetics and 
gender. This has lead to significant diagnostic and treatment challenges; despite treatment 
being fairly common, gaps in our understanding of the pathogenic mechanisms 
contributing to disease have left up to 30-50% of patients refractory to treatment (Souery 
et al., 2006).  
 
Stress dysregulation as a vulnerability marker for neuropsychiatric disease 
Responding to stress is a normal, homeostatic response of the body and brain to a 
perceived threat or challenge. It is vital to an organism’s survival, allowing appropriate 
allocation of energy and attention. However, an inability to cope with stress exposure is a 
well-documented vulnerability marker of neuropsychiatric disease, where patients often 
present with altered basal stress hormones, inappropriate feedback following stress 
exposure, and a failure to produce adaptive stress coping responses (Breslau and Davis, 
1986; Koenig et al., 2002; Nestler et al., 2002). Indeed, in addition to subjective 
measurement of behavioral outcome on scales such as the Hamilton Rating Scale for 
Depression (HRSD) or the Young Mania Rating Scale (YMRS), the amelioration of 
stress hormone dysregulation is an increasingly common readout for the success of 
clinical trials in the domain of neuropsychiatry.  
Of relevance to clinical advancement, aspects of stress behavior and physiology 
can be measured with some reliably in animal models, where core components of the 
stress axis are conserved in humans and rodents. Thus, the examination of stress coping 
behavior and physiology is a tractable target for an investigation into the etiology and 
potential treatment of these diseases. This section outlines the role of the corticotropin-
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releasing factor (CRF) and serotonin (5-HT) systems in stress responsivity, and the 
biochemical changes that occur with chronic stress exposure. 
 
Corticotropin-releasing factor (CRF)  
CRF represents an important link between stress and mood regulation (Vale et al., 
1981; Sutton et al., 1982; Stenzel-Poore et al., 1994; Groenink et al., 2002). The classical 
neuroendocrine stress response - activation of the hypothalamic-pituitary-adrenal (HPA) 
stress axis - is initiated upon stress-induced release of CRF from the paraventricular 
nucleus of the hypothalamus (PVN).  In parallel to its hypothalamic release, extra-
hypothalamic CRF serves as an important neuromodulator to orchestrate stress 
responsivity within the brain (Bale and Vale, 2004).  
Originating largely from the bed nucleus of the stria terminalis (BNST) and 
central amgydala (CeA), in addition to the PVN, CRF acts on two G-protein coupled 
receptor (GPCR) subtypes, CRFr1, and CRFr2. Characterization of transgenic mice that 
have been constructed to lack either CRFr1 or CRFr2 have aided in our understanding of 
the role of these receptors in stress related behavior and physiology. CRFr1-/- mice have a 
blunted stress response and display reduced anxiety-like behavior (Smith et al., 1998; 
Timpl et al., 1998). Conversely, mice lacking CRFr2 are hypersensitive to stress 
exposure, displaying augmented HPA stress axis corticosterone levels, increased anxiety-
like behavior, and reduced ability to mount appropriate coping responses to stress 
exposure (Bale et al., 2000; Bale and Vale, 2003; McEuen et al., 2008). Because of this, 
the two CRF receptors have been described as playing opposing roles as the “gas” and 
“breaks” of the stress response. However, as biology generally teaches us, their roles are 
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not strictly dichotomous. This is evidenced by the generation of mice deficient for both 
CRFr1 and CRFr2, which exhibit a more blunted stress response compared to CRFr1 null 
mice (Bale et al., 2002). Clearly, the cell type and brain region of localization plays a 
critical in the response of these receptors to CRF. 
 
Serotonin (5-HT) 
Serotonin (5-hydroxytryptamine; 5-HT), a monoaminergic neurotransmitter, is 
produced by almost every organ in the body, including the skin, gut, liver, and lungs. In 
the brain, its primary sources are the dorsal and medial divisions of the raphe nucleus 
(DR), which sits below the cerebral aqueduct at the junction of the midbrain and 
brainstem. Despite there being relatively few 5-HT producing neurons, they innervate 
much of the brain and regulate many aspects of behavior (Dahlström and Fuxe, 1964; 
Steinbusch, 1981; Azmitia and Gannon, 1982). The most studied roles of 5-HT are in the 
modulation of arousal, sleep, memory, and mood.  
Because selective 5-HT reuptake inhibitors (SSRIs), which target the 5-HT 
transporter, SERT, have had some success for the treatment of depression, this 
neurotransmitter system has been a major focus of research on mood disorders.  
Serotonin turnover rates are reduced in major depression, and increase with recovery 
(Asberg et al., 1976; Asberg et al., 1984). Alterations in 5-HT signaling have also been 
identified in patients with depression, including reduced 5-HT metabolites in the CSF and 
postmortem tissue, and reduced SERT levels (Reddy et al., 1992; Owens and Nemeroff, 
1994; Huang et al., 2010; Chatzittofis et al., 2013). Single nucleotide polymorphisms in 
the promotor regions encoding for tryptophan hydroxylase-2 (TPH2), the rate-limiting 
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enzyme in the synthesis of 5-HT, has also been found correlated with depression (Gao et 
al., 2012). Polymorphisms in the promoter region of the 5-HT transporter have also 
associated with increased stress-induced depressive symptoms (Ho et al., 2013). 
Interestingly, this SERT polymorphism appears to have a greater impact on the 
depressive symptoms of women compared to men (Sjoberg et al., 2006).  
5-HT also plays an important role in the “manic” side of the behavioral spectrum, 
influencing arousal, impulsivity, hedonic and hyper-aggressive behaviors, all of which 
are central manifestations of mania (Shiah and Yatham, 2000; Crockett et al., 2010). 
Clinical studies of CSF, platelet assessments, and neuroendocrine challenge, and 
postmortem tissue provide evidence to support the hypothesis that serotonin deficiency is 
involved in mania, and that enhancement of serotonin neurotransmission may exert a 
mood-stabilizing effect (Shiah and Yatham, 2000). 
Importantly, there are major sex differences in the 5-HT system, which are 
thought to contribute to sex differences in neuropsychiatric disease, including the 
aforementioned behaviors associated with both depression and mania. Human PET 
imaging has revealed a reduced rate of serotonin synthesis (Nishizawa et al., 1997) and 
differences in 5-HT binding sites throughout the brains of women compared to men 
(Jovanovic et al., 2008). Rodent studies have demonstrated that 5-HT-increasing 
pharmacological agents, which are known to activate the HPA axis, show a greater effect 
on glucocorticoid production in female rodents compared to males (Goel and Bale, 2010). 
Central 5-HT levels and CSF concentrations of the 5-HT metabolite, 5-HIAA, too, appear 
to be higher in females compared to males (Rosecrans, 1970).  
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Biochemical changes following chronic stress 
 The consequences of stress are dependent on specific stressor characteristics, 
including intensity, controllability, and predictability. Importantly, they are also heavily 
dependent on the duration of exposure, which is generally categorized as acute or 
chronic. Chronic stress enhances both basal HPA tone and stress responsivity, often 
resulting in hypersecretion of glucocorticoids and adrenal hypertrophy. Chronic stress 
also impacts central stress circuitry, downregulating glucocorticoid receptors and 
reducing glucocorticoid negative feedback efficacy [reviewed in (Herman, 2013)]. Major 
stress responsive brain regions such as the hippocampus, amygdala, and prefrontal cortex, 
all undergo structural remodeling following chronic stress exposure (Vyas et al., 2002). 
Stress-induced changes in dendritic morphology have been observed in the dentate gyrus 
of the hippocampus (Wood et al., 2004), amygdala (Vyas et al., 2003), and medial 
prefrontal cortex (Liston et al., 2006). Interestingly, cortical changes may be particularly 
plastic, as they display substantial recovery by 3 weeks after the termination of stress 
exposure (Radley et al., 2004). Similar changes occur in these brain regions with chronic 
corticosterone administration, suggesting the effects of chronic stress may be 
glucocorticoid-mediated. This possibility is supported by a study that found treatment 
with 3-β-hydroxysteroid dehydrogenase, which blocks stress-induced corticosterone, 
prevents stress-induced dendritic remodeling in the CA3 region of the hippocampus 
(Magarinos and McEwen, 1995).   
Importantly, many of the effects of chronic stress in the brain are sex-specific; for 
example, chronically stressed males and females show different patterns of 
morphological changes in the hippocampus (Hillerer et al., 2013). Additionally, chronic 
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stress has been shown to decrease norepinephrine, dopamine, and 5-HT in the 
hippocampus of males whereas increased levels of these neurotransmitter levels have 
been observed in females (Sunanda et al., 2000; Beck and Luine, 2002). These findings 
are of particular relevance considering the dramatic sex differences in behavior that occur 
following chronic stress.  
 
Inflammation as a risk factor for neuropsychiatric diseases 
 The CNS contains a blood-brain-barrier (BBB) consisting of endothelial cells and 
astrocytes, which regulates the permeability of entry into the brain. This includes the 
regulation of immune cellular and molecular infiltration from the periphery. The question 
of how the brain and peripheral immune system communicate is still largely under 
investigation. Since cytokine and chemokine receptors are expressed by both glia and 
neurons in the adult brain, a humoral route of communication from the periphery has 
been proposed. Additionally, autonomic nerve fibers provide a loop of communication 
between the brain and peripheral blood vessels, which contain circulating immune cells.  
The brain also contains specialized cells capable of performing immune 
surveillance and repair [reviewed in (Ousman and Kubes, 2012)]. Microglia, astrocytes, 
and neurons all display some immune function through their ability to produce and 
respond to pro- and anti-inflammatory cytokines, express cytokine and chemokine 
receptors, and display inducible expression of major histocompatibility complex (MHC). 
Microglia are generally considered the “resident immune cell” of the brain, where they 
function to survey and clean-up (i.e. phagocytose) damaged or intrusive cells. Microglia 
can promote inflammation through secretion of soluble factors, including TNFα, IFNγ, 
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IL-1β, and several chemokines. Additionally, they can serve an anti-inflammatory role 
through production of IL-4, IL-10, and TGF-β, as well as BDNF and GDNF. Astrocytes 
can play a similar pro- or anti-inflammatory function, though their role as immune cells is 
far less well examined. However, posed at the intersection of the BBB, astrocytic release 
of cytokines and chemokines can play an important role in regulating BBB permeability 
and promoting infiltration of peripheral immune cells.  
Activation of inflammatory signaling cascades have been a promising 
environmental risk factor for the development of a number of neuropsychiatric disorders. 
Schizophrenia, bipolar disorder, depression, and other psychotic illnesses commonly co-
present with immune dysfunction (Muller et al., 2009; Modabbernia et al., 2013). 
Furthermore, there is significant co-presentation of primary immunological disorders 
with psychiatric manifestations. Notably, patients with synaptic autoimmune encephalitis 
are often first admitted into care on the basis of symptoms of mania (Rosenfeld and 
Dalmau, 2011), and the neuropsychiatric manifestations of multiple sclerosis, lupus, and 
rheumatoid arthritis include depressive episodes, irritability, mood swings, rapid speech, 
distractibility, and impulsivity, in addition to cognitive decline (Kwentus et al., 1986; 
Bruce, 2008; Meszaros et al., 2012).  Consequently, many researchers have hypothesized 
that (neuro)immunological mechanisms drive aspects of neuropsychiatric symptomology 
[reviewed in (Najjar et al., 2013)]. However, the complex nature of disease presentation, 
and the difficulty in modeling these complex disorders in animals, has left advancement 
stalled; while there is substantial epidemiological evidence, the understanding of 
mechanisms underlying this link is still very much in its youth.  
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The bidirectional relationship between stress and neuroinflammation 
The first observation that stress impacts immunity came when Hans Selye noted 
that chronic stress results in atrophy of the thymus (Selye, 1936). Since then, stress has 
historically been considered immunosuppressive. Indeed, glucocorticoids, the steroid 
hormone produced by the adrenal cortex in response to stress exposure, play a well-
appreciated anti-inflammatory and immunosuppressive role throughout the body, acting 
through both genomic and non-genomic modes of action (Coutinho and Chapman, 2011) 
(Silverman and Sternberg, 2012) 
Within the brain, however, these stress-induced neuropeptides and hormones can 
actually serve a pro-inflammatory role (Sorrells and Sapolsky, 2007; Sorrells et al., 
2009). Acute stress has been shown to enhance NF-κB activity (Madrigal et al., 2001), 
increase IL-1β (Nguyen et al., 1998), activate TNF-α (Madrigal et al., 2002), and 
upregulate prostaglandins and cyclooxygenase-2 (Madrigal et al., 2003). Importantly, 
stress exposure has been clearly documented to increase inflammatory cytokine 
production in humans and in rodent models (Reyes et al., 2003; Deak et al., 2005; 
Hueston et al., 2011; You et al., 2011).  
Conversely, pro-inflammatory cytokines also have the ability to modulate 
neurotransmitter systems in the brain to affect stress related behavior and physiology 
(Konsman et al., 2002; Johnson et al., 2004; Gadek-Michalska et al., 2013). Most 
notably, IL-1β, TNF-α, and IL-6 can all stimulate glucocorticoid release through HPA 
axis activation at the level of the hypothalamus. This sequence of events has the potential 
to create a dangerous positive feedback loop, whereby increased stress exposure sets a 
stage of vulnerability for an elevated neuroimmune response to stress, which, in turn, 
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increases stress responsivity. In a chicken or egg type of scenario, elevated basal 
neuroinflammation, due to environmental or genetic influence, could also predispose 
individuals to susceptibility for stress-related disorders. 
 
Brain-wide, and region-specific neuroinflammation  
Animal models have clearly demonstrated the ability of pro-inflammatory 
cytokines, such as interleukin (IL)-1β, interferon-γ, tumor necrosis factor-α, and 
lipopolysaccharide (LPS) to modulate arousal and coping behaviors when administered 
peripherally (Dantzer et al., 2008). Intriguingly, the same molecules alter discrete aspects 
of behavior when delivered intracerebroventricularly, or acutely into specific brain 
regions, suggesting that access to and action on particular brain areas may be central to 
their effects (Song et al., 2006; Huang et al., 2008; Barrientos et al., 2012; Hayley et al., 
2013).   
Toxoplasma gondii (T. gondii) is an intracellular obligate parasite with the ability 
to cross the blood-brain-barrier and induce neuroinflammation. In the chronic stage of 
infection, neuroinflammation is maintained, while peripheral infection is cleared. As 
such, T. gondii is a powerful tool to ask about the impact of brain-wide 
neuroinflammation on behavior, both in humans and rodents. What T. gondii infected 
individuals have taught us, is that neuroinflammation has a profound ability to increase 
impulsivity, incidence of schizophrenia, and risk of suicide (Alvarado-Esquivel et al., 
2013; Ingram et al., 2013; Webster et al., 2013). The hypothesis that the location of the 
parasite might influence the behavioral outcomes of infection is not new, and in fact, was 
recently reviewed by McConkey and colleagues (McConkey et al., 2013). 
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Observations of patient behavior in association with measured loci of insult has 
helped to greatly improve our understanding of the impact of brain region-specific 
neuroinflammation on behavior. For example, traumatic brain injury (TBI) and stroke 
both result in a focal neuroinflammatory response, and commonly present with a host of 
neuro-cognitive challenges. TBI, the result of mechanical force applied to the skull and 
transmitted to the brain, leads to psychiatric problems in as many as 40% (Kim et al., 
2007) and secondary mania in close to 9% of patients. Post-stroke depression occurs in 
roughly 30% of survivors (Ayerbe et al., 2013). As such, it has been proposed that TBI 
and stroke impact behavior through disruptions in neurotransmission in relevant 
behavior-coordinating brain regions, termed, the “lesion location perspective.” However, 
data to support this theory remain inconclusive, largely due to the fact that neuroimaging 
methods are not yet able to assess the full extent of the TBI- and stroke-affected areas 
with the precision necessary to denote sufficient anatomical specificity. However, with 
the current rate of advancement in neuroimaging, it is likely that information will soon be 
available.  
Clearly the brain is not a homogenous organ, therefore understanding loci of 
neural dysfunction may help in our understanding of disease etiology, presentation, and 
treatment. Recent studies have found evidence for the presence of focal 
neuroinflammation in a number of psychiatric diseases, including autism (Onore et al., 
2012; Theoharides et al., 2013), depression (Hercher et al., 2009), schizophrenia (Cagnin 
et al., 2007), and bipolar disorder (Rao et al., 2010). These findings suggest that 
anatomical specificity may underlie the epidemiological evidence linking neuroimmune 
and neuropsychiatric disorders.  
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Goals of this dissertation 
 It is becoming clear that neuroinflammaiton can have a profound effect on 
behaviors associated with neuropsychiatric disease. Furthermore, there is mounting 
evidence that impact of neuroinflammation on behavior is driven by brain region 
specificity. However, the mechanism by which this occurs remains unknown, in part due 
to the complex presentation and trajectory of neuropsychiatric disease symptoms. With 
this in mind, the goal of this dissertation was to elucidate the role of neuroinflammation 
as a determinant of stress sensitivity. As there are major sex difference in incidence and 
presentation of both neuroimmune and neuropsychiatric diseases, this thesis also contains 
an examination of sex differences as an additional “model of vulnerability” towards stress 
dysregulation. The hope is that a better understanding of the intersection of 
neuroinflammation, sex, and stress physiology, at a brain region-specific level of 
investigation, may provide the framework to develop more appropriate targets for 
individualized therapeutics. 
 
 
 
 
 
14	  
	  
CHAPTER 2: ANTI-INFLAMMATORY TREATMENT AMELIORATES HPA 
STRESS AXIS DYSFUNCTION IN A MOUSE MODEL OF STRESS SENSIVITY  
 
Alexis R. Gerber* and Tracy L. Bale 
 
Department of Animal Biology, Neuroscience Graduate Group, School of Veterinary 
Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104 
 
 
 
 
 
 
 
 
 
 
This work was originally published in: 
 
Endocrinology. 2012 Oct;153(10):4830-7 
 
 
	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
* Name changed from Gerber to Howerton in 2013 
	  
	  
15	  
ABSTRACT 
 
Dysregulated stress responsivity is a hallmark of neuropsychiatric disease. The 
regulation of stress activation and recovery involves tight coordination between neuronal 
and glial networks. At a certain threshold of sensitivity, stress exposure can evoke a 
neuroimmune response. Astrocytes are potential mediators of these effects, as they are 
able to respond to neuroimmune effector molecules and regulate neuronal activity. Mice 
deficient in corticotropin-releasing factor (CRF) receptor-2 (CRF2-/-) display increased 
stress sensitivity, and are therefore a useful model in which to examine the intersection of 
neuroimmune activation and stress pathway dysregulation. We hypothesized that a 
component of elevated stress reactivity may involve an engagement of neuroimmune 
effectors, including astrocytes. Therefore, we hypothesized that this phenotype may be 
rescued by concomitant non-steroidal anti-inflammatory drug (NSAID) treatment. To 
examine this, mice exposed to chronic stress were treated with NSAIDs in their drinking 
water, and changes in HPA stress axis function were examined. As a correlate of altered 
astrocyte function, levels of glial fibrillary acidic protein (GFAP) were measured. 
Supportive of our hypothesis, NSAID treatment rescued the HPA stress axis dysfunction 
in stress-sensitive CRF2-/- mice, and also reversed the stress-induced increase in GFAP in 
stress-regulating brain regions including the paraventricular nucleus of the hypothalamus, 
ventral hippocampus, and prefrontal cortex. These findings support the local involvement 
of astrocytes in the exacerbation of stress pathway dysregulation. The specificity of these 
effects in a stress-sensitive genotype highlights the importance of utilizing a model of 
stress dysregulation in the examination of factors that may translate to neuropsychiatric 
disease.  
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INTRODUCTION 
Stress pathway dysregulation is one of the most pervasive symptoms in 
neuropsychiatric disease. Patients with stress-related affective disorders, such as anxiety, 
major depressive disorder, and post-traumatic stress disorder often present with altered 
basal stress hormones, inappropriate feedback following stress exposure, and a failure to 
produce adaptive stress coping responses (Breslau and Davis, 1986; Koenig et al., 2002; 
Nestler et al., 2002). Thus, the ability to appropriately respond and adapt to stress at the 
physiological, molecular, and cellular levels are necessary to prevent dysfunction and 
disease. While complex regulatory mechanisms likely contribute to the development of 
neuropsychiatric disease, increasing evidence implicates inflammatory processes in their 
pathophysiology (Strous and Shoenfeld, 2006; Dowlati et al., 2010; Dantzer et al., 2011). 
Within the central nervous system, astrocytes function as immune effector cells capable 
of producing and responding to proinflammatory cytokines, and are intricately involved 
in the integration of signals within neuronal networks (Theodosis and Poulain, 1999; 
Ullian et al., 2004; Allen and Barres, 2005; Volterra and Meldolesi, 2005; Haydon and 
Carmignoto, 2006; Theodosis et al., 2008; Schwarz and Bilbo, 2012). However, how 
such inflammatory processes intersect with stress reactivity is unknown.  
Stress dysregulation and elevated neuroimmune activation commonly co-present 
in psychiatric patient populations, including major depressive disorder and posttraumatic 
stress disorder (Pace and Heim, 2011; Raison and Miller, 2011). However, animal models 
relevant to neuropsychiatric disease rarely consider this dual phenotype. In healthy 
individuals, mild stress exposures do not typically produce neuropsychiatric disease 
symptoms, nor in healthy wildtype (WT) mice does mild stress result in substantial 
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neuroimmune activation (Munhoz et al., 2006). In susceptible individuals, however, 
stressful life events can both precipitate disease onset and exacerbate symptoms 
(MacMillan et al., 2009). Thus, a co-presentation of stress dysregulation and 
neuroimmune activation may only be present in susceptible individuals. Mice deficient in 
corticotropin-releasing factor (CRF) receptor-2 (CRF2-/-) are hypersensitive to stress 
exposure, displaying augmented HPA stress axis corticosterone levels, increased anxiety-
like behavior, and reduced ability to mount appropriate coping responses to stress 
exposure (Bale et al., 2000; Bale and Vale, 2003; McEuen et al., 2008). These stress-
sensitive mice are therefore a useful ‘susceptible’ population in which to examine the 
intersection of neuroimmune activation and stress pathway dysregulation 
Therefore, we hypothesized that stress dysregulation, a significant factor in 
disease susceptibility, involves activation of neuroimmune factors in stress modulating 
brain regions. In addition, the ability to detect such changes may require an appropriate 
stress-sensitive animal model in which stress engages a neuroimmune response involving 
local astrocytes. The current studies examined changes in the astrocyte cytoskeletal 
protein, glial fibrillary acidic protein (GFAP), associated with exposure to chronic stress 
in brain regions central to the regulation of stress responsivity: the paraventricular 
nucleus of the hypothalamus (PVN), hippocampus, and medial prefrontal cortex (Keller-
Wood and Dallman, 1984; Jankord and Herman, 2008; Radley and Sawchenko, 2011). 
To determine if genotypic differences in stress responsivity were related to differences in 
inflammatory processes, concomitant NSAID treatment was assessed for its ability to 
ameliorate stress dysregulation, as evidenced by hypothalamic-pituitary-adrenal (HPA) 
stress axis production of corticosterone and parallel changes in astrocyte GFAP 
	  
	  
18	  
immunoreactivity in key stress-regulatory brain regions.  
 
METHODS 
Animals 
Corticotropin-releasing factor (CRF) receptor-2 deficient (CRF2-/-) mice were generated 
in-house on a mixed C57Bl/6:129J background as described (Bale et al., 2000). Male WT 
and CRF2-/- littermates (14-17 wks) bred from heterozygous crosses were group housed 
under a 12 h light, 12 h dark cycle (lights on at 0600 h), with food and water available ad 
libitum. WT and CRF2-/- mice were randomly assigned to control  (CTL; N = 7-9 per 
genotype) or chronic variable stress (CVS; N = 8-9 per genotype) treatment groups. In 
order to determine if inflammation may be involved in the stress dysregulation found 
after exposure to chronic stress, an additional group received treatment with NSAID 
concomitant with CVS exposure (CVS + NSAID; N = 9 per genotype). All studies were 
performed in accordance with experimental protocols approved by the University of 
Pennsylvania Institutional Animal Care and Use Committee.  
 
Chronic Variable Stress  
Chronic variable stress was comprised of seven mild stressors presented in a randomized 
order for 4 weeks beginning at 14-17 weeks of age. Stressors were specifically selected to 
not directly perturb thermogenic, metabolic, or pain pathways, as described (McEuen et 
al., 2008). Stressors included: overnight wet cage bedding (damp but without standing 
water), 15-min acute restraint, cage change (3 x in a single day), overnight exposure to 
novel objects (eight glass marbles) in cages, overnight novel noise using a white noise 
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generator (Brookstone), 15-min predator odor exposure (fox odor, Acros Organics, NJ; 
diluted 1:10,000), and 36-h constant light exposure. The HPA stress axis assessment was 
administered to all mice and replaced the final stressor. Mice were sacrificed 48 h 
following the HPA axis assessment, and brains were processed for immunofluorescence 
analysis of GFAP. 
 
Non-Steroidal Anti-inflammatory Drug (NSAID) Treatment 
Beginning one week prior to the onset of chronic variable stress and throughout the 
course of the study, CVS + NSAID WT and CRF2-/- mice received acetylsalicylic acid 
(CVS Pharmacy) at 162 mg/L in their drinking water (available ad lib), resulting in a 
dosage of approximately 480 µg/mouse/day (Amateau and McCarthy, 2004). 
Acetylsalicylic acid has been shown to remain stable in water, by fluorescent polarization 
assay, for up to 48 h. Therefore, water (with or without acetylsalicylic acid) was replaced 
every 48 h (Bulckaen et al., 2008). 
 
Hypothalamic-pituitary-adrenal (HPA) axis assessment 
To examine the effects of chronic variable stress exposure and NSAID treatment on the 
HPA axis stress response, plasma corticosterone levels were determined following a 15-
min restraint stress in male WT and CRF2-/- mice (N = 7-9 per genotype/treatment 
group). Testing was administered between 0800–1100 h on the final day of CVS by 
placing mice in a 50 ml conical tube containing a 50 mm air hole. Tail blood samples (10 
µL) were taken at onset and completion of restraint (0 and 15 min, respectively). To 
examine the stress recovery phase, additional samples were collected at 15 min and 75 
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min following the culmination of restraint (30 and 90 min, respectively). Samples were 
collected into 5 µL of 50 mM EDTA, centrifuged, and stored at -80 C until analysis. 
Plasma corticosterone concentration was measured in duplicate using a 125I-
corticosterone radioimmunoassay kit (MP Biomedicals, Orangeburg, NY). The minimum 
detection limit of the assay was 7.7 ng/ml and intra-assay coefficient of variation was 
7.3%.  
 
Immunofluorescence and analyses 
Whole brains were removed from WT and CRF2-/- mice (N = 4) and frozen on dry ice 48 
h after the HPA axis assessment test. Brains were stored at -80 C until cryostat 
sectioning. Frozen tissue was cut on a cryostat into 10 µm coronal sections containing the 
medial prefrontal cortex (Bregma 1.78 to 1.42 mm), paraventricular nucleus of the 
hypothalamus (Bregma -0.58 to -0.94 mm), dorsal hippocampus (Bregma -1.46 to -1.70 
mm), and ventral hippocampus (Bregma -2.80 to -3.16 mm). Every third section was 
thaw-mounted, air-dried on charged slides (Colorfrost® Plus, Fisher Scientific), and 
stored at -80 C. Sections were identified and anatomically matched using the Paxinos and 
Franklin mouse atlas (Paxinos and Franklin, 2003). Immunofluorescence for the 
astrocyte-specific cytoskeletal protein, GFAP, was performed on 3 sections per animal 
per brain region. Slide-mounted fresh frozen sections were fixed for 10 min in ice cold 
acetone, washed 3 times in PBS, and then incubated in 3% normal goat serum and 0.25% 
Triton X 100 in phosphate buffered saline (NGS-PBST) to block and permeabilize, 
respectively. Sections were incubated overnight in rat anti-GFAP polyclonal antibody 
(1:250; Invitrogen, Carlsbad, CA, cat. 130300) in NGS-PBST. Sections were then 
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washed and incubated for 1 h in goat anti-rat Alexa 568 fluorescent secondary antibody 
(1:500; Rockland Immunochemicals, Gilbertsville, PA; cat A-11077) in NGS-PBST. 
Slides were mounted with ProLong gold anti-fade reagent containing DAPI to stain 
nuclei (Molecular Probes/Invitrogen, Carlsbad, CA), and then cured at room temperature 
overnight before image acquisition. Control sections were processed in parallel omitting 
either the primary or secondary antibodies.  
Regions of interest were captured using a 10 bit cooled QICam digital camera 
(QImaging) affixed to a Nikon Eclipse fluorescent microscope at 20X magnification 
(medial prefrontal cortex, hippocampus), or 10X (paraventricular nucleus of the 
hypothalamus). Slides from each brain region were captured at a uniform exposure time; 
however, baseline differences in GFAP between brain regions necessitated different 
exposure times for different brain regions in order to remain within linear dynamic range 
for semi-quantification. Semi-quantitative fluorescence measurements were made within 
a defined region of interest to yield a mean intensity value, using IPLabs for Macintosh 
software (BD Biosciences/Scanalytics).  
 
Serum TNFα  
Trunk blood was collected, mixed with 15 µL of 50 mM EDTA, and centrifuged at 5000 
rpm for 15 min. Plasma was collected and frozen at -80 C. Plasma TNFα levels were 
quantified by sandwich enzyme linked immunosorbant assay (R&D, Minneapolis, MN) 
according the manufacturer’s instructions. The minimum detection limit of the assay was 
7.21 pg/ml and intra-assay coefficient of variation was 3.8%. 
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Statistical Analyses: Corticosterone Radioimmunoassay  
Corticosterone data were analyzed using a repeated-measures MANOVA (genotype x 
treatment x time) with time as a within-subjects repeated measure. To assess magnitude 
of the stress response, area under the curve (AUC) was calculated separately for stress 
response (0 min – 30 min) and recovery (30 min – 90 min) phases. This approach yielded 
an integration of peak response with duration of stressor. A 2-way ANOVA was 
performed on AUC of the response phase and of the recovery phase. Main effects and 
interactions were further explored with Tukey honestly significantly difference (HSD) 
post hoc test. Differences were identified at p < 0.05. Statistical analyses were performed 
with R software (R Foundation for Statistical Computing, Vienna, Austria). Data are 
reported as mean ± standard error of the mean.  
 
Statistical Analyses: Immunofluorescence  
In each brain region, the intensity of GFAP immunofluorescence within a defined region 
of interest was measured in 3 sections per animal. Models that included all possible 
combinations of predictor variables (genotype, treatment, animal) and interaction terms 
were fit to mean fluorescence intensity data and the best-fit model was determined 
according to Akaike’s Information Criterion (AIC). The best-fit model across each brain 
region was a linear mixed model with different intercepts for each mouse. Confidence 
intervals that did not bound zero were considered to hold a measurable effect. Statistical 
analyses were performed with R software (R Foundation for Statistical Computing, 
Vienna, Austria). P values were calculated using the pvalues.fnc package. Data were fit 
to the mixed models using lme4 package. Reported values are based upon parameter 
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estimates of the best-fit model. Error bars represent the observed standard deviation of 
the respective groups.  
 
RESULTS 
HPA axis responses to acute restraint stress  
In order to assess HPA axis stress responsivity, corticosterone levels were measured 
following a 15-min restraint stress (Fig.1). A repeated measures MANOVA of 
corticosterone levels in response to an acute restraint stress revealed a main effect of 
genotype (CRF2-/- > WT) [F(1, 45) = 5.654; p = 0.02]. There was a significant interaction 
between genotype and treatment [F(2, 45) = 3.273; p = 0.048]. Post hoc analysis revealed 
this effect to be driven by augmented corticosterone secretion by CVS-treated CRF2-/- 
mice. NSAID treatment concomitant with CVS exposure prevented the augmented rise in 
corticosterone secretion. A 2-way ANOVA of the area under the curve (AUC) of the rise 
(0 min – 30 min) in corticosterone production revealed a main effect of genotype (CRF2-
/- > WT) [F(1,45) = 6.869; p = 0.012] and treatment (CVS > Control; CVS > CVS + 
NSAID) [F(2,45) = 4.166; p = 0.023]. Analysis of AUC during the recovery phase (30 min 
– 90 min) revealed effects of genotype (CRF2-/- > WT) [F(1,45) = 3.898; p = 0.056] and 
treatment (CVS > Control; CVS > CVS + NSAID) [F(2,45) = 2.657; p = 0.083] that did not 
reach statistical significance. As per our a priori objective, AUC of corticosterone 
production during the recovery phase were compared between CVS and CVS + NSAID 
treatment groups. No significant effect was observed in WT mice; however, NSAID 
treatment significantly attenuated the augmented corticosterone response of CVS-
exposed CRF2-/- mice. 
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Glial fibrillary acidic protein (GFAP) immunofluorescence  
Paraventricular nucleus of the hypothalamus (PVN): Immunofluorescence of GFAP 
was performed on sections from the caudal and rostral PVN (Fig. 2). In the caudal PVN, 
there was a significant interaction [T = -2.185, p = 0.033], whereby NSAID treatment 
decreased GFAP in CRF2-/- mice and increased GFAP in WT mice. GFAP did not 
significantly differ between genotype or treatment groups in the rostral PVN.  
Hippocampus: Immunofluorescence of GFAP was performed on sections from the dorsal 
and ventral CA1, CA3, and dentate gyrus of the hippocampus (Fig. 3). In both the CA1 
and CA3 subregions of the ventral hippocampus there was a significant interaction [T = 
2.138 - 2.16, p = 0.034 - 0.037], whereby CVS increased GFAP selectively in CRF2-/- 
mice. The CVS-induced elevation in GFAP protein was prevented with concomitant 
NSAID treatment. No differences in GFAP were observed in WT animals across any 
treatment group in the ventral CA1, CA3, or dentate gyrus. GFAP did not significantly 
differ between genotype or treatment groups in any of the subregions of the dorsal 
hippocampus.  
Medial prefrontal cortex: Immunofluorescence of GFAP was performed on sections 
from the medial prefrontal cortex (Fig. 4). There was a significant effect [T = 2.048, p = 
0.045], whereby CVS increased GFAP selectively in CRF2-/- mice.  The CVS-induced 
elevation in GFAP protein was prevented with concomitant NSAID treatment. No 
differences in GFAP were observed in WT animals across any treatment group.  
 
Serum TNFα  
All samples were at the minimal level of detection, between 0.056 pg/mL and 0.128 
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pg/mL (data not shown). No significant differences in TNFα were found between 
genotypes [F(1, 38) = 0.02; p = 0.89] or prior exposure to chronic variable stress [F(2, 38) = 
0.16; p = 0.85]. 
 
DISCUSSION 
The aim of the present study was to test the hypothesis that an underlying 
component of elevated stress responsivity involves an engagement of neuroimmune 
responses during chronic stress exposure. We propose that the ability to detect such 
changes requires an appropriately stress-sensitive model. Using CRF2-/- mice as a model 
of stress dysregulation, we uncovered several novel findings: 1) NSAID treatment 
ameliorated augmented HPA axis corticosterone production characteristic of CRF2-/- 
mice exposed to chronic stress; 2) In CRF2-/- mice, GFAP-positive astrocytes increased 
with chronic stress exposure in stress coordinating brain regions, paralleling changes in 
HPA axis corticosterone; 3) NSAID treatment prevented stress-mediated changes in 
GFAP-positive astrocytes. 
 HPA stress axis activity is a physiological indicator of organismal stress state; 
exposure to stress ultimately results in the production of the primary stress hormone, 
corticosterone (Whitnall, 1993). Prior exposure to stress can modify HPA axis activity, 
augmenting or blunting responsivity to novel stressors (Pfister and King, 1976; Bhatnagar 
and Dallman, 1998). While it is necessary to maintain the ability to respond to a novel 
stressor, overactive HPA axis activity can be detrimental. We previously reported that 
exposure to chronic stress in CRF2-/- mice augmented HPA stress axis corticosterone 
levels, evidencing their heightened stress sensitivity (McEuen et al., 2008). In our current 
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study, NSAID treatment during chronic stress completely ameliorated this effect in 
CRF2-/- mice. These findings suggest an underlying neuroimmune involvement in the 
dysregulated stress response, and may suggest a mechanism by which NSAID treatment 
may be efficacious in affective disorder treatment (Muller et al., 2005; Brunello et al., 
2006; Mendlewicz et al., 2006; Muller et al., 2006). 
Astrocytes are a promising mediator of the neuroimmune consequence of stress 
exposure. In select environments, they can both produce and respond to neuroimmune 
effector molecules (reviewed in (Volterra and Meldolesi, 2005)). While numerous end-
feet leave them elegantly poised to respond to and integrate signals within neuronal 
networks, perturbations to astrocytes have the potential for widespread impact, including 
changes in extracellular ionic homeostasis, local neurotransmitter regulation, and 
remodeling of neural circuits (Theodosis and Poulain, 1999; Ullian et al., 2004; Allen and 
Barres, 2005; Haydon and Carmignoto, 2006; Schwarz and Bilbo, 2012). Indeed, 
alterations in astrocyte structural morphology or function have been associated with 
neuropsychiatric illnesses, including depression and schizophrenia (Rajkowska et al., 
1999; Bowley et al., 2002; Toro et al., 2006). Thus, altered astrocyte-mediated plasticity 
may explain why CRF2-/- mice are unable to mount an adaptive coping response to stress 
exposure (McEuen et al., 2008). Therefore, we examined we examined GFAP 
immunoreactivity as a correlate of altered astrocyte function in the PVN, ventral 
hippocampus, and prefrontal cortex, stress-coordinating brain regions.  Consistent with 
our hypothesis, GFAP immunoreactivity increased with chronic stress in CRF2-/- mice 
across these three brain regions. These stress-mediated changes were also prevented with 
concomitant NSAID treatment. Interestingly, GFAP immunoreactivity in the dorsal 
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hippocampus was unaffected by stress exposure. As astrocytes are widely heterogeneous 
in structure and function, and play distinct roles across different brain regions, these 
findings point to a specificity of astrocyte changes that may parallel the specifics of 
dysregulation (Kimelberg, 2004; Lee et al., 2006; Cahoy et al., 2008).  
The PVN is a primary regulator of corticosterone production and is innervated by 
multiple limbic forebrain structures, including the prefrontal cortex and ventral 
hippocampus (Herman et al., 2005). These circuits play important roles in determining 
stressor intensity and in negative feedback (Jankord and Herman, 2008; Radley and 
Sawchenko, 2011). A surprising finding in the PVN was the remarkable increase in 
GFAP positive astrocytes in the WT mice exposed to chronic stress and concomitant 
NSAID treatment. While the explanation for this effect is not currently known, it 
demonstrates important genotypic differences in astrocyte plasticity following stress, and 
may suggest a unique interaction of stress and neuroimmune activation in the normal 
healthy brain that may be beneficial in stress coping (Munhoz et al., 2006).  
CRF receptor-2 is expressed on peripheral immune cells (Lovenberg et al., 1995; 
Baigent and Lowry, 2000). Therefore, to ensure genotype effects detected here were not 
resultant from inflammatory cytokines produced in the periphery, we measured serum 
tumor necrosis factor (TNF)-α in these mice. Levels were below the minimal level of 
assay detection (7.7 pg/ml) for all animals. These findings are consistent with studies 
using similar models of chronic stress exposure that also failed to evoke a significant 
peripheral immune response in the absence of additional immune challenge (d'Audiffret 
et al., 2010; Farooq et al., 2012). These data do not preclude the possibility of peripheral 
inflammation at earlier time points or by other cytokines, but do suggest that changes in 
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neuroimmune modulation have arisen centrally rather than indirectly through activation 
of the peripheral immune system. 
Neuroimmune effectors have been clearly documented to activate the stress 
response, and cytokine treatment can induce symptoms of depression (Tsagarakis et al., 
1989; van der Meer et al., 1996). Taken together, this suggests a potential role for 
immune effectors in stress dysregulation and related phenotypes found in 
neuropsychiatric disease. However, results of several investigations examining the 
neuroimmune response to stress exposure are conflicting; while in some models stress 
drives increases in cytokine production, other models show fewer changes (Bartolomucci 
et al., 2003; Reyes et al., 2003; Deak et al., 2005; Hueston et al., 2011; You et al., 2011). 
Our studies indicate that these differences may be driven by the sensitivity of the model 
utilized. In support of a neuroimmune contribution to the dysregulated stress state, 
NSAID treatment prevented dysregulation of HPA stress axis corticosterone secretion in 
a model of stress sensitivity. Further, chronic stress resulted in upregulation of GFAP by 
astrocytes in the PVN, ventral hippocampus and prefrontal cortex of CRF2-/- mice. The 
current studies provide evidence that not only may NSAID treatment be beneficial in the 
treatment of disorders associated with dysfunctional HPA stress axis, but that it may do 
so through either direct or indirect modification of astrocytes in brain regions involved in 
stress regulation. The specificity of these effects to stress-sensitive animals highlights the 
importance of utilizing a model of stress dysregulation in the examination of factors that 
may translate to human disease. 
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FIGURES AND LEGENDS	  	  
 
 
Figure 2.1 Anti-inflammatory treatment ameliorates chronic stress-induced 
corticosterone elevation in stress-sensitive CRF2-/- mice. Corticosterone levels were 
examined following a 15 min restraint stress (shaded column) in (A) WT and (B) CRF2-/- 
mice. Exposure to chronic variable stress (CVS) enhanced corticosterone production in 
CRF2-/- mice, and this effect was ameliorated by non-steroidal anti-inflammatory drug 
(NSAID) treatment. (C) Corticosterone production during the rise phase (0 min - 30 min) 
was higher in CRF2-/- mice, and was further enhanced during CVS exposure. Concomitant 
NSAID treatment during CVS rescued this outcome. (D) NSAID treatment reversed CVS-
induced total AUC of corticosterone production in CRF2-/- mice. Data are presented as mean 
values ± SEM. (N = 7-9; *, P < 0.05). 
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Figure 2.2 Anti-inflammatory treatment prevents chronic stress-induced increases 
in GFAP in the PVN of stress-sensitive CRF2-/- mice. (A-F) Representative 
immunofluorescence images (10X magnification) of the astrocyte-specific cytoskeletal 
protein, GFAP (red), counterstained with DAPI (nuclei, blue) in the caudal PVN of (A-C) 
WT and (D-F) CRF2-/- mice for (A, D) control, (B, E) following exposure to CVS, or (C, F) 
CVS + NSAID. Bar graphs illustrate semi-quantitative analysis of GFAP 
immunofluorescence. (G) No differences between groups were detected with CVS on 
GFAP in the rostral PVN. (H) In the caudal PVN, NSAID treatment increased GFAP in 
WT, but decreased GFAP in CRF2-/- mice. Atlas images illustrating the brain sections 
analyzed for (I) rostral and (J) caudal PVN, adapted from the mouse atlas (Paxinos and 
Franklin, 2003). Data are presented as parameter estimates of the best-fit model + 
observed standard deviation of respective groups. (N = 3-4; *, P < 0.05). 
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Figure 2.3 Anti-inflammatory treatment prevents chronic stress-induced increases 
in GFAP in the ventral hippocampus of stress-sensitive CRF2-/- mice. (A, B) Brain 
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atlas images illustrating the brain regions analyzed for (A) ventral and (B) dorsal 
hippocampus, adapted from the mouse atlas (Paxinos and Franklin, 2003). Boxes 
highlight region corresponding to image acquisition. (C-H) Representative 
immunofluorescence images (10X magnification) of GFAP (red) counterstained with 
DAPI (nuclei, blue) in (C, F) CA1, (D, G) CA3, and (E, H) dentate gyrus of the ventral 
hippocampus of CVS exposed WT and CRF2-/- mice. (I-K) Bar graphs illustrate semi-
quantitative analysis of GFAP immunofluorescence. CVS increased GFAP in both the (I) 
CA1 and (J) CA3 subregions of the ventral hippocampus selectively in stress-sensitive 
CRF2-/- mice. (K) No differences were observed in the dentate gyrus. (L-Q) 
Representative immunofluorescence images of the (L, O) CA1, (M, P) CA3, and (N, Q) 
dentate gyrus of the dorsal hippocampus of CVS treated WT and CRF2-/- mice. There 
were no significant effects of genotype or treatment on GFAP levels in the (R) CA1, (S) 
CA3, or (T) dentate gyrus subregions of the dorsal hippocampus. Data are presented as 
parameter estimates of the best-fit model + observed standard deviation of respective 
groups. (N = 3-4; *, P < 0.05). 
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Figure 2.4 Anti-inflammatory treatment prevents chronic stress-induced increases 
in GFAP in the medial prefrontal cortex of stress-sensitive CRF2-/- mice. (A-F) 
Representative immunofluorescence images (20X magnification) of GFAP (red) 
counterstained with DAPI (nuclei, blue) in the medial prefrontal cortex (mPFC) of (A-C) 
WT and (D-F) CRF2-/- mice for (A, D) control, (B, E) following exposure to CVS, or (C, 
F) CVS + NSAID. (G) Bar graph illustrates semi-quantitative analysis of GFAP 
immunofluorescence showing significantly elevated levels in the mPFC following CVS 
in CRF2-/- mice. Concomitant treatment with NSAID rescued this effect. (H) Atlas image 
illustrating brain section used for analysis, adapted from the mouse atlas (Paxinos and 
Franklin, 2003). Data are presented as parameter estimates of the best-fit model + 
observed standard deviation of respective groups (N = 3-4; *, P < 0.05). 
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ADDITIONAL DATA 
 
 
Figure 2.5 NSAID treatment rescues chronic stress-induced increase in cFos in the 
DR in response to an acute restraint stress. cFos immunohistochemistry was 
performed on DR brain sections taken from mice 90 minutes after an acute 15 minute 
restraint stress. Data are presented as mean values ± SEM (N = 4-6). *, P < 0.05 
following 3-way ANOVA of genotype x CVS x NSAID. 
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Figure 2.6 NSAID treatment rescues chronic stress-induced reduction in TPH+ 
neurons in the DR. TPH immunoreactivity was assessed in the DR of mice after 28 days 
of chronic variable stress. Data are presented as mean values ± SEM (N = 4-6). *, P < 
0.05 following 3-way ANOVA of genotype x CVS x NSAID. 
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ABSTRACT 
Women are twice as likely as men to suffer from stress-related affective disorders. 
Corticotropin-releasing factor (CRF) is an important link between stress and mood, in 
part through its signaling in the serotonergic dorsal raphe (DR). Development of CRF 
receptor-1 (CRFr1) antagonists has been a focus of numerous clinical trials, but has not 
yet been proven efficacious. We hypothesized that sex differences in CRFr1 modulation 
of DR circuits may be key determinants in predicting therapeutic responses and affective 
disorder vulnerability. Male and female mice received DR infusions of the CRFr1 
antagonist, NBI 35695, or CRF, and were evaluated for stress responsivity. Sex 
differences in indices of neural activation (cFos) and co-localization of CRFr1 throughout 
the DR were examined. Whole-cell patch-clamp electrophysiology assessed sex 
differences in serotonin neuron membrane characteristics and responsivity to CRF. Males 
showed robust behavioral and HPA axis responses to DR infusion of NBI 35695 and 
CRF, whereas females were minimally responsive. Sex differences were also found for 
both CRF induced DR cFos and CRFr1 co-localization throughout the DR. 
Electrophysiologically, female serotonergic neurons showed blunted membrane 
excitability, and divergent IPSC responses to CRF application. These studies demonstrate 
convincing sex differences in CRFr1 activity in the DR, where blunted female responses 
to NBI 35695 and CRF suggest unique stress modulation of the DR. These sex 
differences may underlie affective disorder vulnerability and differential sensitivity to 
pharmacologic treatments developed to target the CRF system, thereby contributing to a 
current lack of CRFr1 antagonist efficacy in clinical trials. 
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INTRODUCTION 
Stress-mediated affective disorders such as depression and anxiety show a marked 
sex disparity, affecting women at nearly twice the rate of men (Kessler et al., 1994; 
Kessler et al., 2005a). Corticotropin-releasing factor (CRF) represents an important link 
between stress and mood regulation (Vale et al., 1981; Sutton et al., 1982; Stenzel-Poore 
et al., 1994; Groenink et al., 2002). Studies have suggested that stress-induced elevations 
in CRF contribute to neuropsychiatric disease development through excessive activation 
of its type 1 receptor, CRFr1 (Britton et al., 1986; Skutella et al., 1998; Smith et al., 1998; 
Timpl et al., 1998; Contarino et al., 1999; Habib et al., 2000; Keck et al., 2003; Muller et 
al., 2003; Gehlert et al., 2005). Consequently, CRFr1 has received considerable attention 
as a novel pharmaceutical target for the treatment of stress-related affective disorders; 
GlaxoSmithKline, Pfizer, Neurocrine Biosciences, DuPont/Bristol-Myers Squibb, and 
others have developed CRFr1 small molecule antagonists toward this end (recently 
reviewed in (Paez-Pereda et al., 2011)). However, despite compelling results for 
antidepressant-like and anxiolytic-like effects of these drugs in pre-clinical studies in 
rodents and nonhuman primates (Deak et al., 1999; Spina et al., 2000; Harro et al., 2001; 
Griebel et al., 2002; Ducottet et al., 2003; Lelas et al., 2004; Nielsen et al., 2004; 
Overstreet et al., 2004; Jutkiewicz et al., 2005), none of the CRFr1 antagonists brought to 
clinical trial over the past decade have successfully completed a Phase III trial (reviewed 
in (Koob and Zorrilla, 2012)).  
Considerable evidence supports the involvement of CRFr1 in stress modulation of 
the serotonergic (5-HTergic) dorsal raphe nucleus (DR) in regulation of mood and affect 
(Price et al., 1998; Valentino et al., 2001; Oshima et al., 2003; Hale and Lowry, 2011). 
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Robust sex differences exist across the stress-serotonin system, where females exhibit 
greater corticosterone and behavioral (anxiogenic) responses to acute selective 5-HT 
reuptake inhibitor (SSRI) treatment (Carlsson and Carlsson, 1988; Nishizawa et al., 1997; 
McEuen et al., 2009; Goel and Bale, 2010). A disruption in the ability of CRF to regulate 
5-HT circuits during chronic stress is implicated in affective disorder pathophysiology 
(Bale et al., 2002; Lowry, 2002; McEuen et al., 2008; Wood et al., 2013). Thus, we 
hypothesized that sex differences in CRFr1 activation within the DR may contribute, in 
part, to an increased female predisposition to stress-induced affective disorders, and may 
underlie disparities between predicted outcomes from preclinical studies and those in 
clinical trials for CRFr1 antagonists.  
 
METHODS 
Subjects 
A total of 268 adult male and female littermate mice were used for all experiments. Mice 
were maintained under a 12-hour light/dark cycle with ad libitum access to food and 
water. For behavioral experiments and electrophysiological studies, C57Bl/6:129S/J F1 
hybrid were obtained from the Jackson Laboratory or bred in house. For CRFr1 
colocalization studies, mice with fluorescent-labeled CRFr1 containing neurons were 
generated as previously described (Justice et al., 2008). Mice were implanted between 
ages 7 and 8 weeks, allowd to recovery for at least one week, and behaviorally tested in 
age-matched cohorts at age 8 to 20 weeks. Mice were singly housed following 
cannulation to prevent disturbance of the cannulae. For electrophysiological experiments, 
slices were obtained from mice at 9 to 13 weeks of age. To mimic the housing conditions 
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of behavioral studies, mice were individually housed for 7 to 12 days prior to recording. 
All studies were conducted in accordance with experimental protocols approved by the 
University of Pennsylvania Institutional Animal Use and Care Committee, and where 
applicable, by the Institutional Animal Care and Use Committee of the Weizmann 
Institute of Science. 
 
Stereotaxic surgery and placement verification 
Mice were anesthetized using isofluorane and implanted with a 26-gauge guide cannula 
(Plastics One, Roanoke, VA) using a stereotaxic instrument (Kopf, Tujunga, CA) 
positioned 1 mm from the DR using the following coordinates (from brain surface): AP -
4.36 mm, ML +1.5 mm, DV –2.0 mm, angled 26 degrees (Takahashi et al., 2010). At the 
end of each study, mice were transcardially perfused and cannula placement was verified 
based on the termination point of the injector as estimated from the location of scar tissue 
in 50 µm sections through the DR. Mice with incorrect cannulae placement were dropped 
from the statistical analysis. Group sizes reported represent the final group size after 
subjects with incorrect placements were omitted. 
 
Drugs and microinfusion 
All drugs were reconstituted in distilled water, aliquotted, and frozen until the day of use. 
Fresh aliquots were dissolved in ACSF (artificial cerebrospinal fluid, Tocris) 
immediately prior to behavioral testing. NBI 35695 (Tocris), a highly selective CRFr1 
antagonist, was used at 0.44 ng, 1000 times the Ki (Martinez et al., 2004). Ovine CRF 
(Sigma) was used because of its higher affinity for CRFr1 (Sutton et al., 1995). 1 ng and 
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50 ng doses were selected based on previous studies of DR infusion of this peptide to 
preferentially target CRFr1 (Lukkes et al., 2008; Bangasser et al., 2010). Drug in 0.25 µL 
ACSF was infused over 1 min through a microinjector attached to polyethylene tubing 
connected to a 10 µL Hamilton syringe on an infusion pump (KD Scientific, Holliston, 
MA). 0.50 µL drug or ACSF was perfused through the microinjector to ensure patency 
between injections.  
 
Hypothalamic-pituitary-adrenal axis assessment 
Testing was performed during a 4-h period beginning 1-h after lights-on. 10uL tail blood 
was collected immediately prior to DR infusion, and at 30, 45, 60, and 120 min post 
injection. Between the 30 and 45 min collections, mice were restrained in a 50 mL 
conical tube with a 5-mm air hole. Samples were collected into tubes containing 5 uL 50 
mM EDTA, centrifuged, and stored at -80°C. Corticosterone concentration was 
determined using a 125I radioimmunoassay kit (MP Biomedicals, Solon, OH). All details 
were followed according to manufacturer’s instructions except volume of sample and all 
solutions were halved.  
 
Behavioral testing 
Behavioral testing was performed on separate cohorts of mice 30 min after drug or ACSF 
infusion. The tail suspension test was carried out as described previously (Steru et al., 
1985; Morgan and Bale, 2011). Mice were secured to a rod by adhesive tape placed ~ 1 
cm from the tip of the tail, and suspended 50 cm from the bench-top in a visually 
isolated, sound-attenuated room. Testing was performed between 0900 and 1400 h. 
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Immobility during the 6-min testing period was hand scored using AnyMaze software 
(Stoelting, Wood Dale, IL). An animal was considered immobile when there was lack of 
all movement except breathing and whisker movement. Immobile time and latency to 
first immobility were determined. The Light-Dark Box was performed as previously 
described (Bale et al., 2000; McEuen et al., 2008). Briefly, light intensity was 5 lux in the 
dark compartment and 175 lux in the light compartment. Test duration was 10 min and 
was performed from 2000 to 0200 h (beginning one hour after lights-off). Anymaze 
software was used to analyze total light time, latency to enter dark, transitions, and 
distance travelled in the light compartment. 
 
cFos immunohistochemistry 
To assess CRF-induced neuronal activation in the DR, double labeling 
immunohistochemistry for cFos and TPH was performed on DR sections. Methods were 
similar to those described previously (Faulconbridge et al., 2008; Goel et al., 2011). 90 
minutes following CRF or ACSF infusion (n=8-9), animals were perfused, and brains 
were post-fixed and stored in sucrose cryoprotectant. Brains were frozen and coronal 
sections (30 um) through the DR were cut using a rotary microtome equipped with a 
freezing stage. Free floating sections (every third section from each mouse) were  washed 
in Tris-buffered saline (TBS), pH 7.4, and incubated for 15 min in TBS containing 0.3% 
H2O2 before being washed again and incubated overnight at room temperature in rabbit 
anti-cFos (1:5,000; Calbiochem, San Diego, CA) diluted in TBS containing 0.2% Triton 
X-100 and 3% normal donkey serum. Sections then were washed in TBS and incubated 
for 2 hr with biotinylated donkey anti-rabbit IgG (1:1000; Jackson ImmunoResearch, 
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West Grove, PA).  After a brief wash with TBS, sections were incubated for 1 hr in an 
avidin–biotin–peroxidase complex (1:333; Elite kit; Vector Laboratories, Burlingame, 
CA). Sections were washed again with TBS and then with 50 mM Tris, pH 7.4, before 
cFos-immunoreactivity was visualized by incubation for 5 min with 3,3-
diaminobenzidine (0.2 mg/ml) and 0.025% H2O2 in 50 mM Tris with 25mg/ml nickel 
sulfate.  The reaction was stopped with TBS washes, after which the sections were 
incubated in H2O2 to quench remaining peroxidase activity, washed briefly and incubated 
overnight at room temperature in mouse anti-TPH (Sigma). Sections then were washed 
before being incubated for 2 hr with biotinylated donkey anti-mouse IgG (1:1000; 
Jackson ImmunoResearch). Sections were washed and incubated in avidin-biotin-
peroxidase complex (1:333; Vector Laboratories) before being washed and reacted with 
3,3-diaminobenzidine (0.1 mg/ml) and 0.025% H2O2 in 50 mM Tris for 5 min. The 
protocol was developed to produce dark, blue-black nuclear cFos-immunoreactivity and 
light brown somatic TPH-immunoreactivity. Sections were floated onto Superfrost plus 
slides (Fisher, Pittsburgh, PA), dehydrated with increasing concentrations of alcohol 
followed by Hemo-De (Fisher Scientific, Pittsburgh, PA), and coverslipped with 
Permount (Fisher Scientific). 
 
Gene expression analysis 
Brains were collected from experimentally naive adult male and female mice (n=5 per 
sex), frozen on dry ice, and stored at -80C. Female brains were all collected in diestrus. 
Brain sections (300 µm) corresponding to figures 66-70 of the Paxinos and Franklin 
mouse brain atlas (Paxinos and Franklin, 2004) were made on a cryostat, and DR 
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micropunches (0.75 µm) were made using a hollow needle (Ted Pella, Redding, CA) and 
collected directly into TRIzol (Invitrogen, Carlsbad, CA) and stored at -80C until RNA 
isolation. RNA was isolated, and cDNA was transcribed as described previously 
(McEuen et al., 2008). Gene expression of CRFr1 (CRFr1; NM_007762.4, 
Mm00432670_m1) CRF-R2 (Crfr2; NM_009953.3, Mm00438303_m1), CRF binding 
protein (Crhbp; NM_198408.3, Mm01283832_m1), TPH2 (Tph2; NM_173391.3, 
Mm00557715_m1), GABA receptor subunits alpha-2 (Gabra2; NM_008066.3, 
Mm00433435_m1), delta (Gabrd; NM_008072.2, Mm01266203_m1), and gamma-2 
(Gabrg2; NM_008073.2, Mm00433489_m1) were determined by quantitative real-time 
PCR using TaqMan gene expression assays (Applied Biosystems, Foster City, CA) (for 
probe information, see Supplementary Methods). Samples were run in triplicate for the 
target gene and for GAPDH as the endogenous control on the same 96-well plate using 
the Applied Biosystems 7500 fast real-time PCR system. For each sample, the cycle 
threshold (CT) value for GAPDH was subtracted from the target threshold value and 
converted to fold change by calculating 2−ΔCT. For each gene, reported values are 
normalized to the average male value. 
 
Immunofluorescence and CRFr1 localization 
To determine whether sex differences exist in the localization of CRFr1 on 5-HTergic or 
GABAergic neurons within the DR, dual immunofluorescence was performed on 
paraformaldehyde-fixed male and female CRFr1-GFP DR. (Sztainberg et al., 2011). 
Parvalbumin (PV) was used to detect a subset of GABAergic neurons in the DR, as it has 
previously been shown to colocalize with most GABAergic neurons in this brain region 
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(Shikanai et al., 2012). TPH, a precursor of 5-HT synthesis, was used as a marker of 5-
HT neurons. Regions of interest were captured at 20x magnification for quantification. 
Representative confocal images were acquired at 40x magnification. Four serial sets of 
DR sections (25 µm) were collected into cryoprotectant (30% sucrose/30% glycerol in 
PBS) and kept at -20°C prior to immunofluorescent processing. One set was dual-labeled 
for GFP and parvalbumin, and a second for GFP and TPH following standard free-
floating immunofluorescent protocol. Both sets were stained concurrently following the 
same procedure and using the same solutions when applicable. All incubations were done 
using 12 well plates (Fisher Scientific, Pittsburgh, PA) with mesh inserts (Ted Pella, 
Redding, CA) on a lab rotator at room temperature unless otherwise specified. 
Pretreatment included a 30 minute incubation in 0.1M glycine, followed by two 1x PBS 
rinses, and 10 minutes in 0.03% SDS. Blocking was done using 4% normal goat or 
normal donkey serum (Jackson ImmunoResearch Laboratory, West Grove, PA), for 
GFP/parvalbumin and GFP/TPH staining respectively, in 0.3% Triton X-100 in 1xPBS 
(0.3% PBST) for 1 hour. Rabbit anti-GFP Alexa Fluor® 488-conjugated antibody (1:500; 
Invitrogen, Carlsbad, CA) was was applied to tissue overnight at 4°C to enhance the GFP 
signal, and sections were simultaneously incubated with either guinea pig anti-
parvalbumin (1:500; Synaptic Systems, Germany) or sheep anti-TPH (1:500; Millipore, 
Temecula, CA). Protein interaction was visualized by incubating sections for 1 hour in 
goat anti-guinea pig or donkey anti-sheep Alexa Fluor® 568 (1:200; Invitrogen, 
Carlsbad, CA). Primary and secondary antibodies were diluted in their appropriate 
blocking solution. Following secondary incubation, sections were rinsed in 1x PBS three 
times,, mounted on Superfrost Plus microscope slides (Fisher Scientific, Pittsburgh, PA), 
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and coverslipped using ProLong Gold Antifade Reagent containing 4,6-diamino-2-
phenylindole (DAPI) to stain nuclei (Invitrogen, Carlsbad, CA). Slides were allowed to 
cure overnight prior to image acquisition.  
GFP-immunoreactive (-ir) cells were quantified from six sections per animal from 
each set of tissue stained. Analysis was conducted on 8-bit grayscale microphotographs. 
The number of GFP-ir cells was measured with the aid of a CellProfiler pipeline 
(Lamprecht et al., 2007; Jones et al., 2008; Vokes and Carpenter, 2008). Cell Profiler 
classified objects were visually confirmed by investigator. The total count of GFP-ir cells 
in each region was averaged between the parvalbumin and TPH sets to produce a single 
value/region/animal. Co-localization counts were performed manually with the aid of Fiji 
software. GFP-ir cells were outlined, and those outlines were superimposed atop either 
parvalbumin or TPH stained images. A cell was considered colocalized if the boundary 
demarcating a GFP-ir cell clearly outlined a parvalbumin+ or TPH+ cell as well.  
 
Electrophysiology 
Immediately upon removal from their home cage, mice underwent cervical dislocation 
followed by decapitation, and the head was placed in a slush of ice-cold artificial 
cerebrospinal fluid (ACSF) in which sucrose (248 mM) was substituted for NaCl. This 
solution was bubbled with 95% O2/5% CO2, and brains were removed while remaining 
submerged in the solution and trimmed to isolate the brainstem region.  Slices (200 µm) 
were cut throughout the rostro-caudal extent of the DR using a vibratome (Vibratome 
3000 Plus), and immediately placed in a holding vial containing ACSF with l-tryptophan 
(50 µM) at 35°C bubbled with 95% O2/5% CO2 for 1 h. Thereafter, slices were 
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maintained in room temperature ACSF bubbled with 95% O2/5% CO2. The composition 
of the ACSF was as follows: 124 NaCl mM, 2.5 mM KCl, 2 mM NaH2PO4, 2.5 mM 
CaCl2, 2 mM MgSO4, 10 mM dextrose, and 26 mM NaHCO3. 
 
Electrophysiology: recording  
Slices were transferred to a recording chamber (Warner Instruments) and continuously 
perfused with ACSF at 1.5–2.0 ml/min at 32–34°C maintained by an in-line solution 
heater (TC-324; Warner Instruments). One cell was recorded per brain slice. Raphe 
neurons were visualized using a Zeiss microscope fitted with a 40x water-immersion 
objective, differential interference contrast and infrared filter (Optical Apparatus). The 
image from the microscope was enhanced using a CCD camera and displayed on a 
television monitor. Whole-cell recording pipettes were fashioned on a P-97 micropipette 
puller (Sutter Instrument) using borosilicate glass capillary tubing (1.2 mm outer 
diameter, 0.69 mm inner diameter; Warner Instruments). The resistance of the electrodes 
was 4 – 8 MΩ when filled with an intracellular solution of the following (in mM): 70 K-
gluconate, 70 KCl, 2 NaCl, 4 EGTA, 10 HEPES, 4 MgATP, 0.3 Na2GTP, 0.1% biocytin, 
pH 7.3. Spontaneous inhibitory post-synaptic potential (IPSC) recordings were made in 
cells located in the dorsomedial subdivision of the DR at the midcaudal level, which 
contains dense clusters of 5-HT neurons, and wherein we observed sex differences in 
cFos in response to CRF infusion. A visualized cell was approached with the electrode, a 
GΩ seal established, and the cell membrane ruptured to obtain a whole-cell recording 
using a Multiclamp 700B patch-clamp amplifier (Molecular Devices). Series resistance 
was monitored throughout the experiment. If the series resistance was unstable or 
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exceeded four times the electrode resistance, the cell was discarded. Once the whole-cell 
recording was obtained, IPSCs were recorded in voltage-clamp mode (Vm =-70 mV). 
Cells were allowed to stabilize and solution dialyze for approximately five minutes while 
a stable baseline was achieved with >-50pA holding current. Signals were digitized by a 
Digidata 1440 series analog-to-digital converter and stored on-line using pClamp 10 
software (Molecular Devices). Signals were filtered at 1 kHz and digitized at 10 kHz. The 
liquid junction potential was ~9 mV between the pipette solution and the ACSF and was 
not subtracted from the data obtained. 
 
Electrophysiology: drug administration protocol 
GABAergic IPSCs were isolated by addition of the non-NMDA receptor antagonist 6, 7-
dinitroquinoxaline-2,3(1H,4H)-dione (DNQX) (20 µM). After a baseline recording of 
spontaneous IPSCs (sIPSCs), GABAergic IPSCs were recorded for 10 min. Ovine CRF 
(30 nM) was then added to the perfusion bath and recorded for 15 min. 
 
Electrophysiology: immunohistochemical identification of 5-HT neurons following 
recording  
Standard immunofluorescence procedures were used to visualize the filled cell and 
tryptophan hydroxylase (TPH) content to identify 5-HTergic cells. Following recording, 
slices were postfixed in 4% paraformaldehyde at 4°C until staining. Sections were then 
blocked for 30 min in phosphate buffered saline (PBS) containing 0.5% Triton and 
bovine serum albumin, and incubated in mouse α-tryptophan hydroxylase antibody 
(1:500; Sigma-Aldrich) overnight at 4°C. Sections were then incubated in FITC-
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conjugated donkey α–mouse secondary antiserum (1:200; Jackson ImmunoResearch) for 
TPH, and streptavidin-conjugated Alexa 647 (1:200; Invitrogen) for biocytin. Both were 
applied for 60 min at room temperature. Between incubations, slices were rinsed in PBS. 
Sections were mounted with ProLong Antifade (Invitrogen) onto charged slides 
(Superfrost Plus, Fisher Scientific). Images were captured with a Leica DMIRE2 
confocal microscope (Leica Microsystems, Exton, PA). 
 
Electrophysiology: analysis 
Membrane characteristics were analyzed using Clampfit as previously demonstrated 
(Crawford et al., 2010; Calizo et al., 2011). Characteristics measured included resting 
membrane potential, membrane resistance, time constant (tau), action potential threshold, 
amplitude and duration, and the afterhyperpolarization (AHP) amplitude. MiniAnalysis 
software (Synaptosoft) was used to analyze mIPSC events on the basis of amplitude, 
duration, and area. Noise analysis was conducted for each cell and amplitude detection 
thresholds set to exceed noise values. Events were automatically selected, analyzed for 
double peaks, and then individually confirmed by visual inspection. Event amplitude 
histograms were compared with the noise histogram to ensure they did not overlap. 
Synaptic activity was analyzed for frequency, amplitude, baseline holding current, rise 
time (calculated from 10 to 90% of peak amplitude), and decay time (calculated by 
averaging 200 randomly selected events and fitting a double-exponential function from 
10 to 90% of the decay phase). The double-exponential function for the decay phase 
generates an initial fast component and a subsequent slow component of the decay phase. 
Data were collected in 1 min bins during the 15 minute period after drug application, 
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taking into account a 2 min lag time from drug addition to initial drug effect attributable 
to recording chamber volume and perfusion rate. The postdrug steady-state value (200 
events or 120 sec, whichever was smaller) was reported as the drug effect for each cell, 
typically occurring 9-12 min after drug application.  
 
Data analysis and statistics 
Total corticosterone was analyzed by multivariate ANOVA (drug x time). Behavioral 
measures were analyzed by two-way ANOVA (sex x drug). Subsequent one-way 
analyses were performed on data within sex, with Dunnett’s test used to identify 
significant post-hoc comparisons. Student’s t-test was used to compare gene expression 
between males and females. To determine CRFr1 counts, a generalized linear mixed 
model was employed to analyze GFP count x sex x subregion using a Poisson 
distribution. Assuming a binomial distribution, further analyses were made to predict the 
likelihood that a given GFP-immunoreactive (-ir) cell co-expressed parvalbumin or TPH. 
Data are reported as estimated effect size ± 95% confidence intervals. Significance was 
determined as p < 0.05, with 95% confidence intervals not bounding 0. Statistics were 
performed in R software. For electrophysiological studies, results of 5-HTergic neuron 
response to CRF were compared between males and females via two-way rmANOVA 
and post hoc Tukey tests employing sex and drug (DNQX vs. DNQX + CRF) as the 
independent variables. Statistics were performed using JMP8 (SAS) software; data are 
reported as mean ± SEM.  
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RESULTS 
DR infusions of NBI 35695 or CRF preferentially alter male corticosterone production  
5-HT output from the DR has modulatory activity on the HPA axis (Lowry, 2002; Goel 
and Bale, 2010). CRF regulation of DR neurons could therefore influence HPA 
responsiveness. Thus, we assessed the effect of CRFr1 antagonism within the DR on the 
corticosterone response to restraint stress (Fig. 1). NBI significantly blunted 
corticosterone levels in males (F(1,9) = 7.085, p = 0.026). The effect of NBI was 
manifested as a reduction in the rise time from 0 to 30 min prior to restraint (t(9) = 3.191, 
p = 0.011) and a reduction in total corticosterone produced throughout the course of the 
experiment (area under the curve, AUC) (t(9) = 2.794, p = 0.021). In females, NBI did not 
significantly impact corticosterone production (F(1,10) = 0.1180, p = 0.7383). We next 
tested the effect of CRF infusion on the HPA axis. In males, CRF significantly increased 
corticosterone (F(1,17) = 5.926, p = 0.026). In females, CRF did not significantly affect 
corticosterone (F(1,18) = 1.28, p = 0.27). 
 
Male-specific effects of DR infusion of NBI 35695 and CRF on stress coping and 
anxiety-like behaviors  
To assess the role of DR CRFr1 in modulating stress coping behavior of male and female 
mice, the TST was performed 30 min following infusion of NBI 35695 or vehicle 
(ACSF) (Fig 2). We detected a significant interaction of sex and NBI on latency to 
become immobile (F(1,37) = 6.654, p = 0.014), where NBI increased latency in males (p = 
0.015), but not in females (p = 0.37). There was a trend towards an interaction effect of 
NBI on immobility in the TST, where NBI reduced immobility in males and increased 
	  
	  
53	  
immobility in females, though this effect failed to reach statistical significance (F(1,40) = 
2.651, p = 0.11). 
The observed sex difference in response to the CRFr1 antagonist suggested 
potential sex differences in the response to CRF. To address this possibility, we next 
assessed the effect of two doses (1 ng, 50 ng) of CRF infusion on behavior in the TST. 
The 1 ng dose of CRF was ineffective to change immobility or latency to become 
immobile on either test, suggesting ineffective local concentrations were achieved. The 
50 ng dose of CRF decreased immobility (F(2,26) = 3.467, p = 0.046) and increased 
latency to become immobile (F(2,26) = 8.684, p = 0.001) in males, and was without effect 
in females.  
To assess anxiety-like behavior, mice were tested in the LD. NBI had no effect in 
either sex on any parameter. However, as with behavioral outcomes in the TST, where 1 
ng dose CRF was without effect, 50 ng dose CRF had sex-specific effects on behavior, 
increasing latency to exit the light compartment (F(2,26) = 5.313, p = 0.011), and total time 
spent in the light compartment (F(2,26) = 5.024, p = 0.014) in males but not females. In 
males, 50 ng CRF also reduced the number of transitions between compartments (F(2,26) = 
4.915, p = 0.016), but did not affect distance traveled in the light (normalized to time 
spent in the light), indicating that the animals did not freeze while in the light 
compartment.  
 
DR infusion of CRF increases cFos in males but decreases cFos in females  
To determine if sex differences in behavioral responsiveness to CRF in the DR were 
associated with differential patterns of neuronal activation, we next assessed cFos 
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immunoreactivity following infusion of CRF or ACSF (Fig 3, Table 1). In males, CRF 
increased the number of cFos-positive cells across the DR (F(1,65) = 14.79, p < 0.001), 
whereas in females, CRF reduced the number of cFos-positive cells (F(1,56) = 7.563, p = 
0.008). Subregion analysis indicated that this interaction was present in dorsomedial 
(F(1,17) = 6.216, p = 0.023), ventromedial (F(1,19) = 5.590, p = 0.029), and lateral wing 
subregions of the DR (rostral, F(1,24) = 7.300, p = 0.013, caudal, F(1,21) = 7.359, p = 0.013). 
CRF had a similar effect of increasing cFos-positive cells in both male and female rostral 
DR (F(1,21) = 12.38, p = 0.002), and no significant main effects were found in the caudal 
DR.  
 
CRFr1 is expressed differentially throughout subdivisions of the DR in males and 
females 
We next assessed whether the observed sex differences in responsiveness the CRFr1 
antagonist or CRF were due to differences in transcript levels of genes relevant to CRF 
and 5-HT signaling. We quantified the relative expression of CRFr1, CRFr2, and CRF-
binding protein mRNA in DR micropunches from experimentally-naïve male and female 
mice (Fig 4a). We observed no difference in the mRNA levels of any of these relevant 
transcripts. As we predict that some of our observed behavioral and physiological 
differences may be GABA-mediated, we also quantified the relative expression of GABA 
receptor subunits alpha-1, alpha-2, delta, and gamma-2, which play important roles in 
receptor kinetics. We observed no sex difference in mRNA in any of these receptor 
subunits. As has been previously described, we detected differences in TPH2, with 
females expressing 1.62-fold higher levels relative to males (t(1,8) = 2.652, p = 0.029) 
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(Rosecrans, 1970; Carlsson et al., 1985; Hiroi et al., 2006). 
After finding no differences in CRFr1 gene expression, we hypothesized that sex 
differences in responsivity to CRFr1 antagonist or CRF may be due to differences in the 
neurotransmitter cell type expressing CRFr1. As current available antibodies are unable 
to distinguish between CRFr1 and CRFr2, we utilized a CRFr1-GFP transgenic mouse in 
which GFP is transcribed under the control of the CRFr1 promoter to identify CRFr1 
positive neurons in the DR (Fig 4b-n) (Justice et al., 2008). Sections throughout the DR 
from these mice were dual labeled for either GFP and parvalbumin to identify putative 
GABAergic neurons expressing CRFr1, or GFP and TPH to identify serotonergic neurons 
expressing CRFr1. In accordance with our CRFr1 mRNA data, there were no sex 
differences in overall number of GFP-ir cells (-0.542 ± -1.59, +0.053; p=0.0796). 
However, we observed a sex difference in co-localization of GFP-ir cells throughout 
regions of the DR. In females, the probability that a given GFP-ir cell co-expressed 
parvalbumin was lower than in males (-2.535 ± -4.819, -0.259; p=0.0291). The 
probability that a given GFP-ir cell co-expressed TPH was less than 25% in all 
subdivisions, regardless of sex, except within the rDR, where males displayed 
significantly more co-localization with TPH than females (-2.16 ± -3.736, -0.583; 
p=0.007). 
 
5-HT neurons in females demonstrate reduced excitability and a blunted response to 
CRF 
To investigate physiological differences in DR 5-HT neurons of males and females, 
whole-cell electrophysiological recordings were conducted using current-clamp and 
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voltage-clamp techniques (Fig 5, Table 2). Data from a total of 21 neurons, using current-
clamp recordings, were analyzed (9 from 6 male mice, 12 from 7 female mice). Cellular 
characteristics that were measured included resting membrane potential, resistance, time 
constant (tau), after hyperpolarization, and action potential amplitude, width, and 
threshold. Characterization of male and female 5-HT neurons revealed females to have a 
significantly depolarized resting membrane potential (t(13) = 2.498, p = 0.027) and a 
reduced tau (t(12) = 2.225, p = 0.046) relative to males. No other membrane characteristics 
differed between males and females. However, a non-linear regression on the frequency-
current (F-I) plot of male and female 5-HT neurons revealed male neurons to have a 
greater excitability (slope) compared to females (F(1,158) = 8.929, p = 0.003), firing at 
27.28 Hz vs. 14.83 Hz, to a maximal injected current of 160 pA.  
 Voltage-clamp recordings of GABAergic IPSCs, isolated by the addition of 
DNQX, revealed several functional differences between male and female 5-HT neurons. 
In response to the addition of CRF (30 nM), males and females showed differential 
changes in the initial first decay time (t(10) = 2.673, p = 0.023), with males showing an 
increase (+2.148 ± 1.376) and females showing a decrease (-2.380 ± 1.045) compared to 
DNQX alone. Males and females also exhibited a divergent CRF-mediated change in rise 
time (t(11) = 2.802, p = 0.0187), and half width (t(11) = 5.994, p < 0.0001); in both 
measures males showed an increase, while females showed a decrease.  
 
DISCUSSION 
Stress-mediated affective disorders display significant sex differences in 
incidence and treatment efficacy (Kessler et al., 1994; Khan et al., 2005). CRFr1 is a key 
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mediator of neuroendocrine and behavioral stress responses, in part through signaling in 
the 5-HTergic DR (Price et al., 1998; Valentino et al., 2001; Oshima et al., 2003; Hale 
and Lowry, 2011). As there are known sex differences in the DR, dysregulation of 5-
HTergic signaling may to contribute to increased disease risk in females (Dominguez et 
al., 2003; Felton and Auerbach, 2004). Development of CRFr1 small molecule 
antagonists has been a major focus in clinical trials for more than a decade, but these 
compounds have been largely unsuccessful. While preclinical studies have predominantly 
been conducted in males, the majority of clinical trials have either focused on female 
patient populations, or have been underpowered to evaluate gender differences in study 
outcomes (Table 1). Therefore, we hypothesized that sex differences in CRFr1 regulation 
of DR circuits are a key determinant in affective disorder vulnerability, and may be 
important in predicting therapeutic outcomes.   
In our studies, male and female mice received an infusion of the CRFr1 small 
molecule antagonist, NBI 35695, or one of two doses of CRF directly into the DR, and 
were evaluated for changes in physiological and behavioral stress responsiveness. NBI 
35695 in the DR significantly blunted corticosterone levels in response to a restraint 
stress only in males. Similarly, CRF infused into the DR in the absence of restraint 
significantly elevated corticosterone production above the levels induced by intracranial 
injection only in males (Kim et al., 1998; Goel and Bale, 2010). The 5-HT system is a 
known activator of the HPA axis, where selective SSRIs and 5-HT agonists increase 
corticosterone production during and independent of stress (Heisler et al., 2007). While 
direct innervation of the PVN has been reported (Petrov et al., 1992, 1994; Williamson 
and Viau, 2007), 5-HTergic fibers from the DR also heavily innervate the GABAergic 
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neurons of the PVN-surround (Sawchenko et al., 1983). Therefore, CRF-mediated 
changes in 5-HT output could modulate this axis through a disinhibition of medial 
parvocellular neurons. We have previously demonstrated sex differences in this pathway, 
with females showing a greater corticosterone response to peripheral SSRI administration 
compared to males (Goel and Bale, 2010; Goel et al., 2011). Thus, a male-specific 
response to administration of NBI 35695 and CRF directly into the DR suggests a unique 
sex-specific mechanism upstream of the PVN, including potential differences in CRFr1 
co-localization or signaling within the DR.  
In our assessment of behavioral stress coping strategies, including the TST, only 
males again showed a significant effect of NBI 35695 to increase the latency to 
immobility, and CRF infusion to reduce the immobile time. While NBI 35695 infusion 
produced no significant changes in male or female mice in the LD, CRF at the higher 
dose again increased time spent in the light and escape latency only in males. These 
findings are consistent with behavioral effects reported in previous studies for 
systemically administered CRFr1 antagonists and CRFr1 gene deletion, implicating the 
DR as a key brain region mediating these outcomes (Smith et al., 1998; Timpl et al., 
1998). Interestingly, in our current studies, both CRF and NBI 35695 infusions produced 
similar effects in the TST. It may be that interactions with CRFr2, which is also found in 
the DR, and/or alternate DR projections may account for differences in this behavior 
(Hammack et al., 2003; McEuen et al., 2008; Neufeld-Cohen et al., 2012). As the DR has 
a heterogeneous cell population involved in the complex regulation of 5-HT 
neurotransmission throughout the brain, the localization of CRF receptors on different 
cell types and their recruitment likely determines specificity in 5-HT release (Valentino et 
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al., 2001; Hale and Lowry, 2011). Similar paradoxical findings have been reported for 
other CNS receptor systems involved in complex behaviors (Dragatsis et al., 1995; 
Alleweireldt et al., 2002). In support of our hypothesis, these data demonstrate striking 
sex differences in stress responses to DR infusion of a CRFr1 antagonist or CRF.  
To test whether sex differences in neuronal activation by CRF may underlie sex 
differences we detected in physiological and behavioral stress responses, we analyzed 
numbers of cFos positive cells following infusion of the behaviorally effective 50 ng dose 
of CRF into the DR. No significant sex differences in basal cFos staining following 
vehicle infusion were detected, suggesting similar basal cellular activation in the DR. 
However, CRF infusion into the DR resulted in a dramatic increase in the number of cFos 
positive cells in males, and a paradoxical reduction in females. This lack of an 
appreciable effect of CRF infusion in females supports the specificity of CRF 
administration to the DR with minimal diffusion into the cerebral aqueduct, as the latter 
would be expected to augment corticosterone irrespective of sex (Dunn and Berridge, 
1990; Goel and Bale, 2010). These sex differences were most apparent in the 
dorsomedial and lateral wings of the DR, regions previously implicated in uncontrollable 
stress and anxiety (Abrams et al., 2004; Abrams et al., 2005; Hale and Lowry, 2011). 
Immunohistochemical evidence supports a dense CRF innervation of these DR 
subregions, where CRF fibers primarily contact GABA-containing dendrites (Lowry et 
al., 2000; Valentino et al., 2001; Waselus et al., 2005). Thus, differences in the number of 
CRF-responsive GABAergic neurons in females could account for the observed reduction 
in activation detected in these mice.  
Within the DR, there is a well-described topographical organization, where 
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GABAergic interneurons exhibit tight control over the tonic and activity-mediated release 
of 5-HT (Valentino et al., 2001; Allers and Sharp, 2003; Hale and Lowry, 2011). To test 
the hypothesis that divergent sex responses to CRF application within the DR may be due 
to differences in CRFr1 localization on functionally distinct neuronal populations, we 
used a CRFr1-driven GFP transgenic reporter mouse line to quantify sex differences in 
co-expression of CRFr1 (Justice et al., 2008). As the available antibodies for the CRF 
receptors are known to be of poor quality and lack sufficient specificity, this reporter 
mouse provided an excellent tool to identify CRFr1-positive neurons in the DR. We 
quantified sex differences in co-expression of GFP with TPH, a marker of 5-HTergic 
neurons, or with parvalbumin, a marker of a subset of GABAergic neurons. Parvalbumin 
was used to mark a GABAergic neurons as 87% of GAD67-ir neurons in the DR co-
express parvalbumin (Shikanai et al., 2012). These neurons may display some functional 
differences compared to the broader population of GABAergic neurons, but were selected 
based on reliable somal immunoreactivity for co-expression analysis with CRFr1 
(McKenna et al., 2013). Overall numbers of CRFr1 neurons did not differ between males 
and females, as indicated by similar numbers of GFP-positive neurons in the DR. This 
was also confirmed by similar expression levels of CRFr1 mRNA in the DR of males and 
females. As expected, few GFP-positive neurons were co-expressed with TPH, consistent 
with previous reports that demonstrate CRF primarily acts on GABAergic neurons, and 
that CRFr1 shows little expression overlap with 5-HT neurons (Kirby et al., 2008). 
Surprisingly, females had reduced GFP co-labeling with parvalbumin compared to males. 
This outcome supports a revised model; rather than females demonstrating greater 
CRFr1-mediated GABA tone, sex differences in CRF-induced neuronal activation may 
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be due to differences in CRFr1 intracellular signaling, trafficking, or receptor kinetics 
(Bangasser, 2013). Such sex differences in CRF signaling have recently been 
demonstrated in the locus coeruleus (Bangasser et al., 2010; Valentino et al., 2013). 
Alternatively, CRF may be activating a population of parvalbumin-negative GABA 
neurons in the female DR. 
Based on our observed sex differences in CRFr1 co-expression, we hypothesized 
that DR 5-HT neurons in males and females may receive differential GABA input in 
response to CRF. To examine this, we used whole-cell electrophysiological recordings to 
measure GABAergic IPSCs in 5-HT neurons before and after application of CRF. We 
observed a striking sex difference in CRF responsivity, where CRF increased IPSC decay 
time in males, but decreased decay time in females. IPSC decay time can correlate with 
the number of activated axonal inputs during the IPSC, suggesting sex differences in 
presynaptic GABAergic input onto 5-HT neurons (Balakrishnan et al., 2009). This is 
consistent with the differential co-expression of CRFr1 on parvalbumin neurons between 
males and females. Further, the reduced IPSC half-width in response to CRF exhibited by 
females also supports this sex difference in the number of GABAergic release sites onto 
5-HT neurons. These differences in IPSC kinetics constitute a significant functional 
difference between males and females that could alter 5-HT neuron excitability and 
neurotransmission, and thereby influence stress physiological and behavioral measures.  
In gathering basal characteristics prior to assessing sex differences in 5-HTergic 
neuron responses to CRF, we uncovered an unexpected sex difference in 5-HT neuronal 
excitability. Using whole-cell patch clamp recordings from 5-HT neurons from male and 
female dmDR slices, we found reduced neuronal excitability in females in response to a 
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series of current injections. In addition to sex differences in CRFr1 localization and 
GABAergic responses to CRF, this suggests that 5-HT neurons in females require a 
greater depolarizing stimulus to generate neuronal firing and subsequent 5-HT release, 
even at baseline. Compared to males, this may translate to 5-HTergic hypofunction in 
females, an underlying risk factor for the development of affective disorders during stress 
exposure (Van de Kar, 1989; Kapitany et al., 1999).  
Overall, these studies revealed intriguing sex differences in behavioral and 
physiological effects of CRFr1 antagonist and CRF in the DR, which were 
mechanistically associated with sex differences in receptor co-expression and divergent 
electrophysiological responses to CRF in 5-HTergic neurons. The blunted response of 
females points to a potential explanation for the lack of efficacy in CRFr1 antagonists in 
clinical trials, which have focused primarily on female participants due to their increased 
disease prevalence (Table 1). These findings support the importance of identifying sex 
differences in central stress pathways in order to understand the heightened 
predisposition of females toward these disorders, and in identifying sex-appropriate, and 
potentially sex-specific, pharmacological treatments.  
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FIGURES AND LEGENDS 
 
	  
 
Figure 3.1 DR infusion of the CRFr1 small molecule antagonist NBI 35965 or 50 ng 
CRF had male-specific effects on HPA responsiveness. (A,C) Time course of 
corticosterone response to a 15 min restraint (indicated by shaded region) in males (A) 
and females (C). (B,D) Area under the curve (AUC) analysis demonstrated a significant 
reduction of corticosterone output by NBI 35965 in males (B), but not in females (D). (E-
H) Corticosterone response to infusion of 50 ng CRF infusion in males (E,F) and females 
(G,H). AUC analysis demonstrated that CRF enhancement of corticosterone release was 
specific to males (F). Data are presented as mean values ± SEM (n=8). *, P < 0.05 in 
comparison to ACSF. 
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Figure 3.2 Males and females show divergent behavioral responses to CRFr1 
antagonism or CRF infusion into the DR. (A,B) Effects of CRFr1 antagonist NBI 
35965 on total immobile time (A) and latency to first bout of immobility (B) in the tail 
suspension test (TST). Males showed a greater latency to immobility.  (C,D) CRFr1 
antagonism had no effect in the light-dark box (LD) on measures of total time spent in the 
light compartment (C) or latency to first exit from the light compartment (D).  (E-H) 
Behavioral effects of 1 ng and 50 ng CRF infusion demonstrated no effect of the 1 ng 
dose, but male-specific effects of the 50 ng dose. 50 ng CRF infusion reduced immobile 
time (E) and increased latency to immobility (F) in males in the TST, and increased both 
total light time (G) and latency to exit the light (H) in males in the LD. Data are 
presented as mean values ± SEM (N= 8 ). *, P < 0.05 in comparison to ACSF. 
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Figure 3.3 A 50 ng CRF infusion elicited differential patterns of neuronal activation 
in males and females across DR subregions. (A-D) Representative dorsomedial 
(dmDR) sections show cFos induction 90 min following CRF infusion is enhanced in 
males (A,B), but reduced in females (C,D).  (E) Fos-positive cell counts from DR 
subregions demonstrate increased counts in males, but reduced counts in females, 
particularly in dmDR and rostral and caudal lateral wing (rLW, cLW) subregions. Values 
represent the difference in mean number of Fos-positive cells in sections from mice 
administered CRF or ASCF.  Data represent the difference in averages from 7-9 mice per 
group. *, P < 0.05. 
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Table 3.1 Quantification of dorsal raphe cFos response to ACSF or CRF infusion 
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Figure 3.4 CRFr1 is expressed on different cell populations in males and females. 
(A) Expression of genes relevant to CRF and serotonergic signaling in the dorsal raphe 
There were no sex differences in mRNA levels of CRFr1, CRFr2, CRF-binding protein 
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(CRF-BP), GABA receptor (GABR) subunits alpha-1 (α1), α2, delta (δ), or gamma-2 
(γ2); however TPH2 was significantly higher in females. Data are presented as fold 
change relative to the mean value in males ± SEM (n=5). *, P < 0.05 compared to males. 
(B) Regional, but no sex differences in number of GFP-ir cells throughout subregions of 
the DR. (C, D) Brain atlas diagrams depict the region viewed in the representative images 
of (C) the rostral lateral wings (rLW) and (D) the dorsomedial (dm) DR. (E-L) 
Representative, split channel confocal images from the rLW (E, G) and the dmDR (I, K) 
highlight these regional differences in GFP expression. Sections were dual-labeled with 
anti-parvalbumin (PV), (F, G) and anti-tryptophan hydroxylase (TPH) (J, K) to identify 
the phenotype of GFP+ cells in the DR. Arrows denote location of GFP-ir cells enlarged 
to illustrate co-localization (single arrow, GFP only; double arrow, co-localized). 
Examples of GFP-ir cell bodies with (left) or without (right) co-localization of PV (H) 
and TPH (L) show that GFP is transcribed by a subset of both types. (M, N) Probability 
that a given GFP-ir cell colocalizes with PV (M) or TPH (N). Females presented with an 
overall reduction in the probability that a given GFP-ir cell colocalizes with PV (N), and 
reduced likelihood that GFP-ir cells within the rostral DR (rDR) colocalize with TPH. 
Data are presented as an average probability ± SEM. *, P < 0.05 in comparison to male. 
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Figure 3.5 Males and females exhibit differences in baseline characteristics, and 
divergent responses to bath applied CRF. (A) Representative IPSC trace. (B-C) Scaled 
IPSC averaged from a single male (B) and female (C) illustrating the effect of DNQX 
and CRF on half-width. Insets (B’,C’) illustrate sex difference in effect of CRF on rise 
time. (D-F) CRF increases rise (D), half-width (E) and decay time (F) in males, and 
decreases these measures in females. (G) Males exhibit increased excitability compared 
to females to a series of current injections. Values represent the difference in response of 
CRF – DNQX. (N = 7-9). *, P < 0.05. 
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Table 3.2 Active and passive cell characteristics of 5-HT neurons 
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Table 3.3 Clinical trials targeting CRFr1 for the treatment of major depression and 
anxiety disorders 
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ABSTRACT 
Impulsivity, risk-taking behavior, and elevated stress responsivity are prominent 
symptoms of mania, a behavioral state common to schizophrenia and bipolar disorder. 
Though inflammatory processes activated within the brain are involved in the 
pathophysiology of both disorders, the specific mechanisms by which neuroinflammation 
drives manic behavior are not well understood. Serotonin cell bodies originating within 
the dorsal raphe (DR) play a major role in the regulation of behavioral features 
characteristic of mania. Therefore, we hypothesized that the link between 
neuroinflammation and manic behavior may be mediated by actions on serotonergic 
neurocircuitry. To examine this, we induced local neuroinflammation in the DR by viral 
delivery of Cre recombinase into interleukin (IL)-1βXAT transgenic male and female 
mice, resulting in overexpressing of the proinflammatory cytokine, IL-1b. For assertion 
of brain region specificity of these outcomes, the prefrontal cortex (PFC), as a 
downstream target of DR serotonergic projections, was also infused. Inflammation within 
the DR, but not the PFC, resulted in a profound display of manic-like behavior, 
characterized by increased stress-induced locomotion and responsivity, and reduced risk-
aversion. Microarray analysis of the DR revealed a dramatic increase in immune-related 
genes, and dysregulation of genes important in GABAergic, glutamatergic, and 
serotonergic neurotransmission. Behavioral and physiological changes were driven by a 
loss of serotonergic neurons and reduced output as measured by HPLC, demonstrating 
inflammation-induced serotonergic hypofunction. Behavioral changes were rescued by 
acute SSRI treatment, supporting the hypothesis that serotonin dysregulation stemming 
from neuroinflammation in the DR underlies manic-like behaviors.  
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INTRODUCTION 
Schizophrenia, bipolar disorder, and other psychotic illnesses commonly co-occur 
with immune dysfunction, where patients exhibit altered cytokine profiles, and 
postmortem tissue indicates neuroimmunological abnormalities (Muller et al., 2009; 
Modabbernia et al., 2013). Brain-wide neuroinflammation can impact behavior, including 
those that are altered in disease. Chronic brain infection with the parasite Toxoplasma 
gondii, for example, has a profound ability to increase impulsivity, as well as the 
incidence of schizophrenia and suicide, even following parasite clearance (Alvarado-
Esquivel et al., 2013; Ingram et al., 2013; Webster et al., 2013). Furthermore, there is 
significant co-presentation of primary immunological disorders with psychiatric 
symptoms. Notably, patients with synaptic autoimmune encephalitis are commonly first 
treated following presentation with manic behavior (Rosenfeld and Dalmau, 2011), and 
the neuropsychiatric manifestations of multiple sclerosis, lupus, and rheumatoid arthritis 
include irritability, mood swings, distractibility, and impulsivity (Kwentus et al., 1986; 
Bruce, 2008; Meszaros et al., 2012). Recent studies have highlighted the important role 
of neuroinflammation as a contributing factor in neuropsychiatric disease [reviewed in 
(Najjar et al., 2013)]. 
Animal models have clearly demonstrated the ability of proinflammatory 
cytokines, such as interleukin (IL)-1β, interferon-gamma, tumor necrosis factor-α, and 
lipopolysaccharide to modulate arousal and coping behaviors when administered 
peripherally (Dantzer et al., 2008). These same molecules alter discrete aspects of 
behavior when delivered intracerebroventricularly, or acutely into specific brain regions, 
suggesting that access to and action on particular brain areas may be central to their 
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effects (Song et al., 2006; Huang et al., 2008; Barrientos et al., 2012; Hayley et al., 2013). 
Brain regions adjacent to sources of cerebrospinal fluid (CSF), which carries circulating 
immune cells, may be particularly susceptible to the effects of inflammation (de Vries et 
al., 1997).  
The serotonergic dorsal raphe (DR) is located in apposition to the cerebral 
aqueduct, making it a potentially vulnerable site for inflammatory insult. Serotonin plays 
a central role in the modulation of arousal, impulsivity, hedonic, and hyper-aggressive 
behaviors, as well as stress responsivity, all of which are central manifestations of mania 
(Shiah and Yatham, 2000; Crockett et al., 2010). In vitro, neuroinflammatory signaling 
molecules, including IL-1β, alter serotonergic neuron excitability and neurotransmitter 
release (Manfridi et al., 2003; Zhu et al., 2006). Clinical studies of CSF, platelet 
assessments, and neuroendocrine challenge, and postmortem tissue provide evidence to 
support the hypothesis that serotonin deficiency is involved in mania, and that 
enhancement of serotonin neurotransmission may exert a mood-stabilizing effect (Shiah 
and Yatham, 2000). Largely due to the challenge of experimental induction of a relevant 
inflammatory trigger, however, the mechanism and anatomical specificity by which this 
occurs remains unknown. 
Here, we used an IL-1βXAT model to induce neuroinflammation with temporal and 
brain region specificity (Shaftel et al., 2007a; Shaftel et al., 2007b; Hein et al., 2010). 
This model has the advantages of sustained IL-1β overexpression, allowing continuous 
cytokine production, and of regional specificity, as release in neuronal projection regions 
or sites of microglial trafficking is prevented through astrocytic-specific production. 
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Using this approach, we tested the hypothesis that neuroinflammation in the serotonergic 
DR can drive manic-like behavior. 
 
METHODS 
Animals 
The construction and characterization of the IL-1βXAT line has been described previously 
(Shaftel et al., 2007a,b). In our studies, IL-1βXAT male mice on a C57BL/6 background 
were bred with 129S/J females to create F1 hybrid mice carrying the IL-1βXAT transgene. 
Justification for using a mixed background strain in these studies is related to stress 
responsive phenotypes and physiology. C57Bl/6 are extremely low stress responders 
making them a less desirable choice for stress studies. 129S/J mice are more robust stress 
responders, but frequently lack a fully formed corpus collusum and can be poor 
performers in behavioral tests. However, the combination of these two strains produces a 
hybrid vigor that serves stress research well with consistent responses and behavioral 
outcomes (McEuen et al., 2008; McEuen et al., 2009; Gerber and Bale, 2012). Both WT 
and transgenic littermates were used in initial behavioral studies. Mechanistic follow-up 
experiments were conducted in transgenic mice only. Because we observed no sex 
differences in behavior or gene expression, immunofluorescence of the DR was 
conducted on brain sections from male mice only. Mice were maintained under a 12-hour 
light/dark cycle with ad libitum access to food and water. All studies were conducted in 
accordance with experimental protocols approved by the University of Pennsylvania 
Institutional Animal Care and Use Committee. 
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Viruses and Stereotaxic Surgery 
Adeno-associated virus (AAV) vectors were produced and purchased from the University 
of Pennsylvania Vector Core (Philadelphia, PA) and injected into 8-10 week old WT or 
IL-1βXAT transgenic littermates. Two viruses were used in this study: AAV2/5 containing 
a transgene for green fluorescent protein (AAV-GFP; AAV2.5.CMV.GFP.WPRE.SV40) 
and AAV2/5 containing transgenes for both GFP and Cre recombinase (AAV-Cre; 
AAV2.5.CMV.GFP.Cre.WPRE.SV40). AAV2/5 was used for its ability transduce glial 
cells (Koerber et al., 2009), which we confirmed in comparison to AAV2/1 and AAV2/9 
in pilot studies. Correct infusion placement was verified by visualization of GFP in 300 
µM sections containing the DR. For viral infusions, mice were anesthetized using 
isoflurane, before a 33-gauge needle attached to a 10 µL Hamilton syringe was 
positioned within the DR using a stereotaxic instrument (Kopf, Tujunga, CA), according 
to the following coordinates (from brain surface): AP -4.36 mm, ML + 1.5 mm, DV 
3.625 mm, angled 26 degrees (Takahashi et al., 2010). 0.25uL of virus diluted to 1.0e10 
GC with sterile artificial cerebrospinal fluid was administered over the course of 1 min. 
Based on pilot testing of the time course of viral gene expression, and to allow for 
adequate recovery time, behavioral testing began 5 weeks after. All males were infused 
within a 3-day time window, followed by all females, again within a 3-day time window, 
one week later.  
 
Immunofluorescence 
Six weeks after surgery, animals were perfused with ice-cold phosphate buffered saline 
(PBS) followed by 4% paraformaldehyde. Whole brains were removed, post-fixed in 4% 
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paraformaldehyde overnight, and transferred to 30% sucrose solution for 48 h. Brains 
were then removed from solution and stored at -80°C until cryostat sectioning. Tissue 
was cut on a cryostat into 4 serial sets of 30 µm coronal sections containing the DR, and 
stored in cryoprotectant (30% sucrose, 30% glycerol, in PBS) at -20°C until staining. 
Sections were identified and anatomically matched using the Mouse Brain Atlas (Paxinos 
and Franklin, 2001). 1 set of DR sections from each animal was stained in each antibody. 
TPH-stained sections were first pre-treated with a 30 min incubation in 0.1M glycine 
followed by a 10 min incubation in 0.03% SDS. All sections were then washed 3 times in 
PBS, and incubated in 3% normal goat serum and 0.25% Triton-X 100 in phosphate 
buffered saline (NGS-PBST) to block and permeabilize, respectively. Sections were 
incubated overnight in the appropriate primary antibody (rat anti-GFAP at 1:250, 
Invitrogen, Carlsbad, CA, cat. 130300; sheep anti-TPH at 1:500, Millipore, Temecula, 
CA, cat. AB1541; mouse anti-NeuN at 1:500, Chemicon, Billerica, MA cat MAB377B) 
in NGS-PBST. Sections were then washed and incubated for 1 h in goat anti-rat Alexa 
568 fluorescent secondary antibody (1:500; Rockland Immunochemicals, Gilbertsville, 
PA, cat. A-11077) in NGS-PBST. Slides were mounted with ProLong gold anti-fade 
reagent containing DAPI (Molecular Probes/Invitrogen, Carlsbad, CA) to stain nuclei, 
and then cured at room temperature overnight before image acquisition. Control sections 
were processed in parallel omitting the primary antibodies. A separate cohort of animals 
was sacrificed without perfusion to better identify immunological markers, and brains 
were immediately frozen on dry ice and stored at -80°C until cryostat sectioning. These 
sections were cut at 10 µm directly onto slides, air dried overnight, and then post-fixed 
for 20 min in ice-cold acetone. Sections were processed for the immunological markers 
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rat anti-CD11b (M1/70, 1:500, eBiosciences, San Diego, CA, cat. 14-0112-81) and rat 
anti-IDO (1:500; BioLegend, San Diego, CA, cat. 122402) as above, omitting any pre-
incubation steps.  
Regions of interest were captured using a 10-bit cooled QICam digital camera 
(QImaging, Surrey, British Columbia) affixed to a Nikon Eclipse fluorescent microscope 
at 20X magnification. Slides for each antibody were captured at a uniform exposure time; 
however, baseline differences in immunofluroescence between antibodies necessitated 
different exposure times for different antibodies in order to remain within linear dynamic 
range for semi-quantification. Semi-quantitative fluorescence measurements were made 
within a defined region of interest to yield a mean intensity value, using IPLabs for 
Macintosh software (BD Biosciences/Scanalytics, San Jose, CA). Cell counts for TPH-ir 
cells were performed with the aid of CellProfiler, as previously described (Howerton et 
al., 2013).  
 
LacZ detection 
4 sets of four 30 µm sections were made from the DR of six animals, which were 
perfused 8 weeks following AAV-Cre infusion, and three animals following AAV-GFP 
infusion. One set of each was used to assess LacZ as an indicator of transgene expression 
(Shaftel et al., 2007b). Sections were collected into cryoprotectant (30% sucrose, 30% 
glycerol in PBS) and stored at 4°C until processing. Sections were transferred to PBS the 
day before LacZ staining, and washed on a rotator overnight. Sections were then 
transferred to a solution containing 0.1% X-Gal (5-bromo-4-chloro-3-indolyl β-D-
galactopyrano-side), 2 mM MgCl2, 5 mM potassium ferricyanide, and 5 mM potassium 
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ferrocyanide for 24 h at 37°C. Sections were washed twice in PBS, successively 
dehydrated in 75%, 95%, and 100% ethanol, and left in Citrisolv prior to coverslipping. 
Sections were mounted with Permount, and allowed to dry overnight before image 
acquisition. Images were captured using a 10-bit cooled QICam digital camera 
(QImaging, Surrey, British Columbia) at 4X and 40X. Sections were manually assessed 
for LacZ-positive cells through visualization of punctate blue staining.  
 
Behavioral testing 
Behavioral testing was performed beginning 5 weeks after surgery targeting the DR in 
the following order: elevated plus maze, light-dark box, hypothalamic-pituitary-adrenal 
(HPA) axis stress test. A separate cohort was used in the locobox. Behavioral testing on 
animals infused with virus into the prefrontal cortex were tested in the elevated plus maze 
and light-dark box followed by an HPA axis stress test. All behavioral testing was 
performed by an experimenter blinded to mouse genotype and treatment. Males and 
females were tested in separate cohorts (males, followed by females) to allow testing at 
equal days post-surgery, and to prevent the influence of female odor on male behavior. 
All behavioral data are therefore presented as within-sex comparisons.  
 
Elevated plus maze 
Mice were placed in the center of the maze facing an open arm at the beginning of the 5 
min test. Light intensity in the open arms was 6 lux. All testing occurred 2-5 h after lights 
off. Distance traveled and time spent in each arm was analyzed by AnyMaze software. If 
a mouse fell off the open arm, the test was paused and the animal was placed back in the 
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center of the maze. If the animal fell off the maze more than once, this was noted and 
they were excluded from analysis. 
 
Light-dark box 
Mice were placed in the light compartment at the beginning of the 10 min test session. 
Light intensity was set at 175 lux in the light compartment. All testing occurred 2-5 h 
after lights off. Total distance traveled, time spent in the light compartment, and 
transitions between the light and dark compartments were analyzed with ANY-maze 
v4.75 software (Stoelting). Methods were similar to those described previously (McEuen 
et al., 2009). 
 
LocoBox 
The locobox consists of a two-compartment apparatus connected by a 6 cm throughway. 
Mice were placed in the center of the wide compartment (25 cm x 27 cm), built to the 
size of the light compartment of the light-dark box, facing the narrow entry at the 
beginning of the 10 min test. The narrow compartment (8 cm x 84.375 cm) lay adjacent 
to the wide compartment, giving equal floor space to traverse (675 cm2) but in a confined 
space, similar to the closed arm of the elevated plus maze. Light intensity in the wide 
compartment was set at 300 lux. This novel test was employed following testing on the 
light-dark box and elevated plus maze for several reasons. First, it was used as an 
additional measure of stress-induced locomotion. Additionally, as equal floor space was 
given in both the open and closed compartments, it prevented the potential confounding 
interpretation of choice of side preference (as in the light-dark box). Lastly, it tested the 
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possibility that the animals experienced a claustrophobic reaction to the closed 
compartment of the elevated plus maze, which would explain their preference for the 
open arm, rather than differences in risk-taking, general arousal, or anxiety-like behavior. 
All testing occurred 4-9 h after lights on. Distance traveled and time spent in each zone 
were recorded, tracked, and analyzed by AnyMaze software.  
 
Hypothalamic-pituitary-adrenal (HPA) axis assessment 
Testing was performed over a 4-h period beginning 1-h after lights-on. 10uL tail blood 
was collected at 0, 15, 30, and 90 min. Between 0 and 15 min time points, mice were 
restrained in a 50 mL conical tube with a 5-mm air hole. Corticosterone was determined 
by radioimmunoassay (MP Biomedicals, Orangeburg, NY) using 3 µL plasma with a 
variance coefficient of R2 = 0.9985, as previously described (Gerber and Bale, 2012). 
 
Gene expression microarray 
Whole brains from behaviorally tested animals were cryosectioned at -20°C. Using a 
hollow needle (Ted Pella, Redding, CA), three 0.75 mm punches containing the DR from 
300 µM slices were micropunched according to the Mouse Brain Atlas (Paxinos and 
Franklin, 2001). Punches were bath sonicated for 2.5 min (30 s on/off cycles) in TRIzol 
reagent (Invitrogen). RNA was isolated by RNeasy kit (Qiagen) and suspended in RNase-
free water. Total RNA was sent to the University of Pennsylvania Path BioResources 
Molecular Profiling Core for Affimetrix GeneChip Mouse Gene 1.0 ST analysis.  
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Quantification of biogenic amines 
Levels of monoamine neurotransmitters were determined using high performance liquid 
chromatography (HPLC) as described previously (Stein et al., 2006) with 
modifications.  Animals were sacrificed by rapid cervical dislocation, and brains were 
dissected and immediately frozen on dry ice to be stored at -80°C until processing. 
Thereafter, eight 1 mm punches containing the medial prefrontal cortex or three 0.75 mm 
punches containing the DR from 300 µm slices were collected from AAV-GFP- and 
AAV-Cre-infused animals into homogenization buffer (22 mM sodium acetate, 75 mM 
glacial acetic acid, 0.05 mM EDTA, pH 4.95) containing 100 nM 3,4-
dihydroxybenzylamine (DHBA) as an internal standard, and stored at -80°C.  On the day 
of the HPLC analysis, samples were thawed on ice, sonicated in a bath sonicator (3 5-sec 
pulses) and centrifuged at 21,000 x g for 20 min at 0°C.  30 µL of tissue sample was 
combined with 5 µL of ascorbate oxidase (0.3 mg/ml), and 20 µl of this mixture was 
injected. Samples were injected onto a C18 reverse-phase column (ODS, 150 × 4.6 mm; 
5 µm particles; Thermo Electron Corporation, Waltham, MA) by a Waters (Milford, MA) 
717 Plus Autosampler, eluted using an isocratic system with a mobile phase (MD-TM; 
ESA, Bedford, MA) containing 1.0 mM 1-octanesulfonic acid, and pumped by a Waters 
515 HPLC pump. Under these conditions, norepinephrine (NE), serotonin (5-HT), 5-
hydroxyindole-3-acetic acid (5-HIAA), dopamine (DA), 3,4-dihydroxyphenylacetic acid 
(DOPAC), and homovanillic acid (HVA) were clearly resolved.  External standards 
ranging from 0 to 2 pM were interspersed within the run and the 2 pM standard was 
injected twice (first and last) to determine whether there had been any drift during the 
analysis. A Coulochem III electrochemical detector equipped with a 5011A analytical 
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cell (ESA) was used to detect the biogenic amines. Data were captured using the 
Empower 2 Software system (Waters). 
 
Drug treatment 
To examine the hypothesis that serotonergic hypofunction is a causal factor in the 
behavioral dysfunction observed following DR neuroinflammation, an acute dose of 
citalopram (30 mg/kg, i.p.; Abcam, Cambridge, United Kingdom), a selective serotonin 
reuptake inhibitor, was administered 32 min prior to testing on the Elevated Plus Maze. 
This dose and time course was selected based on the ability to acutely modulate serotonin 
levels and affect serotonin-mediated behaviors (Griebel et al., 1994; McEuen et al., 2009; 
Mombereau et al., 2010), while having no affect on locomotion (Umehara et al., 2013).  
Our choice of timing was slightly adjusted from the literature (32 minutes instead of 30 
min prior to testing) to stagger mice appropriately, allowing for the testing of all animals 
of one sex to be performed within one test session. Drug was prepared fresh and 
distributed into syringes prior to the first injection.  
 
Data analysis and statistics 
Behavioral measures were analyzed within sex by two-way ANOVA (genotype x virus 
treatment), with Tukey’s test used to identify significant post-hoc comparisons. Total 
corticosterone was analyzed within sex by multivariate ANOVA (genotype x drug 
treatment x time). Statistics were performed using JMP8 (SAS) software; data are 
reported as mean ± SEM. Microarray data were modeled comparing AAV-GFP vs. AAV-
Cre in accordance with behavioral and physiological data using R (version 2.14.2) and 
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the packages arm, bbmle, and limma to fit optical density data to linear models, and 
estimates for main and inter-action effects were determined from these models. Database 
for Annotation, Visualization, and Integrated Discovery (DAVID) functional annotation 
clustering was used for determination of gene clusters that significantly differed between 
groups. The top five gene clusters are shown in the figure. Heat maps and hierarchical 
clustering were performed using MuliExperiment Viewer (TM4.org) with Pearson’s 
correlation. HPLC analysis was performed by t-test, comparing IL-1β infused with AAV-
GFP vs. AAV-Cre. Repeated testing on the elevated plus maze during the citalopram 
rescue experiment was conducted within sex by two-way ANOVA (treatment x trial), 
with post-hoc testing comparing citalopram treatment to each of the saline treatments. 
Significance was set at p<0.05.   
 
RESULTS 
Interleukin-1β overexpression within the dorsal raphe produces a local 
neuroinflammatory response 
We utilized an IL-1βXAT mouse (generously provided by M.K. O’Banion, University of 
Rochester), where chronic IL-1β overexpression is inducible under the control of a glial 
fibrillary associated protein (GFAP) promoter upon delivery of Cre recombinase. This 
model allows both spatial and temporal control of IL-1β-mediated neuroinflammation. 
These mice have been previously described as displaying a robust, long-lasting 
neuroinflammatory response characterized by increased GFAP expression, microglial 
ramification, and MHCII expression (Shaftel et al., 2007a; Shaftel et al., 2007b). Here we 
show that with a small viral delivery (0.25uL), we are able to induce a 
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neuroinflammatory response that is contained within the DR (Fig. 1). Stereotaxic 
infusion of an adeno-associated virus (AAV) 2.5 containing Cre recombinase and GFP 
(AAV-Cre) into the DR of IL-1βXAT mice (Fig. 1A) led to spatially restricted LacZ 
expression (Fig. 1B), and GFP expression (Fig. 1C), indicating viral transduction within 
the DR. This resulted in a 1.7 log-fold increase in the IL-β transcript within the DR (Fig. 
1D) (F(1,24) = 182.2, p < 0.0001). Neither AAV-GFP infusion into IL-1βXAT mice nor 
AAV-Cre or AAV-GFP infusion into WT littermates resulted in detectable LacZ 
expression (data not shown). In AAV-Cre IL-1βXAT mice we observed robust microglial 
activation (Fig. 1E), as indicated by CD11b expression and ramified morphology of 
CD11b-ir cells. We also observed differences in neuronal morphology (NeuN) in AAV-
GFP infused animals (Fig. 1F) compared to AAV-Cre infused animals (Fig. 1J), and 
profound glial activation, as indicated by robust GFAP and aquaporin-4 (AQP4) 
immunoreactivity in animals infused with AAV-Cre (Fig. 1K, L) compared to animals 
infused with AAV-GFP (Fig. 1G, H). Interestingly, we observed a notable nuclear 
localization of the tryptophan catabolic enzyme indoleamine 2,3-dioxygenase (IDO) 
expression in mice infused with AAV-Cre (Fig. 1M), whereas IDO was undetectable in 
AAV-GFP animals (Fig. 1I). Importantly, these DR changes were not associated with an 
increase in circulating IL-1β, as measured by enzyme-linked immunosorbant assay 
(F(1,29) = 0.4631, p = 0.5016) (Fig. 1N). 
 
Raphe neuroinflammation promotes dysregulated stress behavior and physiology 
To test the hypothesis that the serotonergic DR is responsible for aspects of 
neuroinflammation-mediated behavioral dysfunction, animals were behaviorally tested on 
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the elevated plus maze, light-dark box, and locobox beginning 5 weeks after viral 
infusion (Fig. 2). In the elevated plus maze (Fig. 2A-F), we detected a significant 
interaction of genotype (WT vs. IL-1β) and virus (AAV-GFP vs. AAV-Cre), where both 
male (Fig. 2A-C) and female (Fig. 2D-F) IL-1β mice infused with AAV-Cre spent more 
time in the open arms (F(1,30) = 27.12, p < 0.0001; F(1,24) = 23.08, p < 0.0001) (Fig. 2B, E). 
In the males, there was a significant effect of genotype (F(1,30) = 5.439, p = 0.0266 ) and 
virus (F(1,30) = 11.44, p = 0.002) on total distance traveled, where IL-1β mice infused with 
AAV-Cre traveled a greater distance throughout the test than the other groups (Fig. 2A). 
In females this presented as a significant interaction (F(1,24) = 8.376, p = 0.008) (Fig. 2D). 
Intriguingly, transgenic IL-1β mice infused with AAV-Cre spent a substantial amount of 
time at the distal ends of the open arms (males: 34.73 ± 6.8 sec, females: 48.40 ± 15.981 
sec), whereas few of the WT mice or AAV-GFP infused mice ever entered the distal ends 
of the open arms (Fig. 2C, F). In the light-dark box (Fig. 2G-L), we detected a 
significant interaction effect of genotype and virus, where both male (Fig. 2G-I) and 
female (Fig. 2J-L) IL-1β mice infused with AAV-Cre traveled a greater distance when 
normalized to time spent in light compartment (F(1,27) = 7.525, p = 0.011; F(1,25) = 13.49, p 
= 0.001) (Fig. 2G, J) and had a faster speed of travel (F(1,27) = 7.607, p = 0.010; F(1,25) = 
12.99, p = 0.0014) (Fig. 2H-N), and spent more time in the light compartment of the box 
(Fig. 2I, L).  
We performed additional testing of novelty-induced locomotion on an additional 
cohort of IL-1β mice infused with AAV-GFP or AAV-Cre in the locobox (Fig. 2M-T). 
In this task, where animals were given equal floor space to traverse in an open or narrow 
compartment, we recapitulated genotype by treatment effect on locomotive arousal in 
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both sexes, where males (Fig. 2M-P) showed increased distance traveled (t(1,8) = 4.127, p 
= 0.003) (Fig. 2M) and females (Fig. 2Q-T) showed the same pattern (t(1,9) = 1.909, p = 
0.088). Both males and females infused with AAV-Cre displayed increased speed (t(1,8) = 
4.122, p = 0.003; t(1,9) = 1.915, p = 0.089), while showing no preference towards either 
the open or narrow compartments.  
In our assessment of neuroendocrine stress responsivity, as measured by 
corticosterone production in response to an acute restraint stress, we found that male IL-
1β mice infused with AAV-Cre produced significantly more corticosterone compared to 
any of the other control groups, displaying a significant interaction effect of genotype by 
treatment by time (F(2,18) = 8.1046, p = 0.0014) (Fig. 3A). Females showed the expected 
higher corticosterone curve compared to males (F(1,40) = 71.345, p < 0.0001), however 
there was no significant interaction of genotype by treatment by time to further increase 
their corticosterone levels (F(2,18) = 0.1243, p = 0.9445) (Fig. 3B).  
 
Acute IL-1β  infusion affects only locomotion 
We next assessed the impact of an acute IL-1β infusion within the DR to better elucidate 
the difference between the effects of acute IL-1β, and the consequences of chronic IL-1β-
mediated neuroinflammation, the latter of which being more disease relevant. We found 
that an acute infusion of IL-1β directly into the DR increased locomotion (Fig. 4A), as 
measured by distance traveled throughout the elevated plus maze (F(1,22) = 4.649, p = 
0.043), but had no significant effect on time spent in the open arm (Fig. 4B) (F(1,21) = 
0.7403, p = 0.340). Further, acute IL-1β failed to elicit the risk-taking behavior of 
exploration onto the distal ends of the open arms where none of the animals entered the 
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distal ends during the test (Fig. 4C). Of note, all animals in this study had reduced 
locomotor activity compared to the animals in the transgenic study, likely due to the 
stress of intracranial infusion 30 min prior to behavioral testing, and as expected the 
magnitude of locomotor effects are much smaller than those seen with IL-1βXAT mice, 
and none of the mice in this study ventured into the distal ends of the open arms. 
 
The behavioral consequences of neuroinflammation are brain region-specific 
To assess whether the impact of neuroinflammation on behavior is brain region-specific, 
we performed parallel experiments to induce IL-1β overexpression in the prefrontal 
cortex, a region which receives dense serotonergic input, is involved in relevant 
behaviors, and is also implicated in bipolar disease and schizophrenia (Lewis, 2012; Price 
and Drevets, 2012; Mann, 2013). When we assessed the behavioral consequences of 
neuroinflammation in this brain region, we observed no significant effect on behavior or 
physiology (Fig. 4). Animals performed similarly in the elevated plus maze (Fig. 4A-C) 
and light-dark box (Fig. 4D-E), and exhibited no difference in corticosterone response to 
an acute restraint stress (Fig. 4F-G). 
 
Changes in gene expression following raphe neuroinflammation  
Given the observed behavioral results, we undertook an investigation of the molecular 
mechanisms that may lead to the increased manic behavior seen with DR 
neuroinflammation. We carried out gene expression profiling studies using microarray to 
evaluate global change in basal gene expression in the DR of males and females 
following AAV-GFP or AAV-Cre infusion two weeks after the culmination of behavioral 
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testing (Fig. 5). We detected robust changes in gene expression, with 4,873 genes 
showing significant differences, as determined by an FDR of 0.01 (Fig. 5A). Functional 
annotation clustering of these affected genes with a fold change of at least 1.1 revealed a 
significant enrichment for 177 gene clusters (Fig. 5B), which were primarily involved in 
inflammatory signaling. This analysis also identified enrichment for the Kyoto 
Encyclopedia of Genes and Genomes (KEGG) Pathway for apoptosis, suggesting some 
degree of cell death in this brain region. 66 gene clusters were identified as significantly 
down-regulated (Fig. 5C), the top 20 of which were found to be involved in 
neurotransmission, ion transport, axon/dendrite morphology and function, and steroid 
biosynthesis. In order to identify transcriptional changes that would be most relevant to 
our hypothesis that neuroinflammation mediates behavioral changes via its effects on 
neurosignaling within the DR, we conducted a further sub-analysis on genes annotated 
with any gene ontology (GO) term containing “neur*” to identify genes specifically 
related to neuron/signaling. This analysis revealed a list of 26 genes corresponding 
primarily to serotonin, GABA, glutamate, and potassium signaling and transport (Fig. 
5D). 
 
Dorsal raphe neuroinflammation results in serotonergic hypofunction 
The DR is home to the majority of serotonergic neurons, and we observed changes in 
behavior indicative of serotonergic dysfunction. Therefore we investigated the potential 
changes in the neurochemistry following IL-1β overexpression in a separate cohort of 
male mice (Fig. 6). We first quantified tryptophan hydroxylase-immunoreactive (TPH-ir) 
neurons within the DR following AAV-GFP or AAV-Cre infusion to assess whether 
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neuroinflammation has the potential to broadly change the population of serotonergic 
neurons. AAV-Cre infused animals had significantly fewer TPH-ir cells in the 
dorsomedial DR (t(1,10) = 4.787, p = 0.0007) compared to AAV-GFP infused animals 8 
weeks following viral infusion (Fig. 6A-C). No differences in TPH-ir were detected in 
the lateral wing subregions of the DR (t(1,10) = 0.434, p = 0.670), indicating local 
specificity of these effects. To assess functional consequences, the concentration of 
norepinephrine (NE), dopamine (DA), and 5-HT and their major metabolites, 
dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), and 5-
hydroxyindoleacetic acid (5-HIAA) were measured in the PFC and DR. Within the DR, 
there was a substantial reduction in NE (t(1,12) = 6.766, p < 0.0001) (Fig. 6E), with no 
difference in DA (t(1,12) = 0.492, p = 0.632) (Fig. 6F). In the PFC, a major DR output 
region, there was less 5-HT (t(1,11) = 2.232, p = 0.047) (Fig. 6H), more 5-HIAA (t(1,11) = 
2.748, p = 0.019) (Fig. 7I), and greater turnover (t(1,11) = 6.368, p < 0.0001) (Fig. 7J). No 
significant differences were found in NE or DA in the PFC (data not shown).  
 
Acute citalopram treatment ameliorates behavioral dysfunction following IL-1β-
induced neuroinflammation in the DR  
To test the hypothesis that the observed behavioral dysfunction was the result of an 
inadequate pool of available 5-HT during the acute behavioral testing, we next assessed 
whether pharmacological elevation in 5-HT would rescue the behavioral phenotype 
caused by DR neuroinflammation. To do this, male and female mice were repeatedly 
tested on the elevated plus maze following i.p. injection of 30 mg/kg citalopram to 
acutely elevate 5-HT levels (Fig. 7). As observed in previous cohorts, saline-injected 
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AAV-Cre-infused animals had an increase in total distance traveled throughout the test 
(F(1,7) = 14.13, p = 0.0071) (Fig. 7A, C), and spent significantly more time exploring the 
open arms of the maze (F(1,7) = 26.87, p = 0.0013) (Fig. 7B, E) and the distal ends of the 
open arms (F(1,7) = 18.18, p = 0.0037) (Fig. 7C, F). Repeated measures ANOVA revealed 
a significant interaction effect of citalopram treatment to ameliorate open arm time (F(2,14) 
= 4.380, p = 0.0333), distance traveled (F(2,14) = 8.557, p = 0.0037), and end of open arm 
entries (F(2,14) = 5.168, p = 0.0186) in AAV-Cre-infused male IL-1β mice (Fig. 7A-C). 
Females showed the same pattern in all measures, with significance reached in measures 
of open arm time (F(2,12) = 6.359, p = 0.0131) (Fig. 7D-F). Post-hoc testing in these 
parameters indicated significant difference of saline treatment (injection 1 and 3) from 
citalopram treatment (injection 2), indicating the citalopram effect was not one of 
repeated testing. IL-1β mice infused with AAV-GFP animals showed decreased 
exploration over repeated testing, as expected, with no effect of citalopram 
administration.  
 
DISCUSSION 
Impulsivity, risk-taking behavior, and elevated stress responsivity are prominent 
symptoms of mania, a state of hyper-arousal common to schizophrenia, bipolar disorder, 
and other psychotic illnesses. Epidemiological evidence suggests that inflammation 
within the brain plays a role in the pathophysiology of these diseases (Najjar et al., 2013). 
However, the mechanistic link between neuroinflammation and the development of 
manic-like behavior remains unknown, though likely involves serotonin, which plays a 
central role in modulating relevant behaviors. Through the use of an IL-1βXAT transgenic 
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model of brain region-specific neuroinflammation, we tested the hypothesis that 
neuroinflammation within the serotonergic DR is able to recapitulate aspects of manic-
like behavior.  
The manic-like phenotypes that we observed following IL-1β-mediated 
neuroinflammation in the DR were striking, reminiscent of recently defined examples of 
manic-like behavior in mouse models (Han et al., 2013; Kirshenbaum et al., 2013; Saul et 
al., 2013). Across several behavioral paradigms, animals displayed increased novelty-
induced locomotion and a disinhibited exploration of adverse environments (e.g., distal 
ends of the open arm in the elevated plus maze). These features, coupled with the 
observed increase in neuroendocrine stress responsivity, closely resemble the behavioral 
and physiological dysregulation observed in schizophrenia and bipolar disorder. Patients 
with schizophrenia, for example, exhibit emotional over-arousal to neutral social scenes 
(Haralanova et al., 2012), engage in risky sexual behavior associated with a higher 
incidence of sexually transmitted infections (Ramrakha et al., 2000), and present with 
exacerbated symptoms in the face of stress exposure (Jones and Fernyhough, 2007). 
Patients with bipolar disorder, as well, show increased exploration and novelty seeking 
(Minassian et al., 2011), engage in high-risk behaviors such as gambling (Chandler et al., 
2009), and exhibit a hyperactive neuroendocrine response to stress (Watson et al., 2004). 
The effects we observed appear to be mediated by the neuroinflammation following IL-
1β, as an acute administration of IL-1β directly into the DR did not impact these aspects 
of manic-like behavior. Serotonergic cell bodies within the DR play a central role in the 
regulation of the behavioral features of mania (Homberg and Lesch, 2011; Bortolato et 
al., 2013). Thus, the observed changes in behavior are highly suggestive of a 
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recapitulation of neuroinflammation-induced mania in an animal model that may be 
driven by alterations to the serotonergic system.  
We predicted an anatomical specificity to the effects, and tested this hypothesis 
by conducting parallel experiments targeting the PFC, which receives dense serotonergic 
input from the DR, and thus is an important downstream mediator of the behavioral 
effects of serotonin. Serotonin signaling within the PFC is critical for impulse control and 
cognitive flexibility, where depletion results in capricious and perseverative behavior 
(Clarke et al., 2004). Indeed, there is evidence for reduced serotonin in the prefrontal 
cortex of patients with schizophrenia (Sumiyoshi et al., 2013). Neuroinflammation 
localized to this key serotonergic output region was insufficient to alter behavior, 
suggesting that inflammatory signals alter serotonin-mediated behavior via effects on the 
serotonergic cell bodies at the level of the DR.  
Therefore, we next evaluated the impact of our manipulations on gene expression 
within the DR, focusing both on broad programmatic changes, as well as those of 
particular relevance to neurotransmission and serotonergic signaling. The microarray 
revealed a predicted increase in inflammation-related genes, consistent with our 
immunofluorescent characterization of the model. More interestingly, genes related to 
serotonin, GABA, glutamate, and noradrenergic neurotransmitter systems were 
profoundly decreased in the DR, suggesting dramatically altered neuronal excitability, 
synaptic transmission, and ability to adapt to external input. This imbalance is consistent 
with the ability of IL-1β to directly inhibit spontaneous serotonergic neuron firing in vitro 
(Manfridi et al., 2003). Additionally, IL-1β has recently been shown to play a role in 
modulating glutamate transmission in the experimental autoimmune encephalomyelitis 
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(EAE) model of multiple sclerosis (Mandolesi et al., 2013), supporting the ability for IL-
1β to modulate neurotransmission and regulate serotonergic neuron excitability and 
output. 
Based on the directionality of transcriptional changes, we hypothesized that there 
may be fewer serotonin-producing neurons within the DR. This was confirmed 
immunohistochemically, where we observed a 30% reduction in overall TPH-ir neurons. 
This may be the result of a downregulation of TPH itself (i.e., reduced detection of TPH-
ir), or to a loss of serotonergic neurons. In the same animals, HPLC analysis revealed 
reduced serotonin output to the PFC. While 5-HT was measured in the PFC as one 
readout of DR serotonergic output, this is likely predictive of a brain-wide reduction in 5-
HT. Interestingly, DR lesions have previously been shown to increase exploration in the 
open arm of the elevated plus maze, consistent with our findings of serotonergic 
hypofunction and an increase in apoptosis-related gene expression in the DR (Briley et 
al., 1990). Therefore, the effect of neuroinflammation within the DR could be due to 
reduced serotonergic responsivity, neuron number, or ability to produce serotonin.  
To further test this hypothesis, we employed a pharmacological strategy to rescue 
the phenotype of these mice by treatment with the selective serotonin reuptake inhibitor 
(SSRI), citalopram, to rapidly increase serotonin availability. We found that a single dose 
of citalopram ameliorated the behavioral dysfunction of IL-1β mice infused with AAV-
Cre on the elevated plus maze. These animals spent less time in the open arm, had fewer 
visits to the end of the open arm, and had an overall reduction in hyperlocomotion 
compared to their original performance one week earlier. Importantly, when animals 
were re-tested again following vehicle treatment, the direction of their behavior returned 
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towards a dysregulated state. The transient rescue of behavior demonstrates that reduced 
serotonin does indeed play a causal role in the manic-like behavior observed following 
DR neuroinflammation. However, as behavior was not restored completely to control 
levels it is also possible that having fewer serotonin-producing neurons could have 
reduced the effectiveness of the drug to raise serotonin levels sufficiently and/or that an 
acute increase in available serotonin does not completely compensate for the chronic 
dysregulation within the DR. 
One possible co-existing mechanism that could contribute to the observed 
behavioral dysfunction is an increase in lipocalin-2 (Lcn2), a suggestion that is supported 
by our microarray dataset in which Lcn2 displayed a 2.5 log-fold increase in expression. 
Lcn2, an iron-binding sideophore, is commonly increased in response to inflammatory 
insult due to its ability to deprive bacteria of necessary iron. Thus, it serves as an 
important protective role in the case of bacterial infiltration. Pathological consequences 
of Lcn2 upregulation, however, are substantial. Tryptophan hydroxylase (TPH), the rate-
limiting enzyme in the synthesis of serotonin, requires iron for proper enzymatic activity 
(Nakata and Fujisawa, 1982a, b). Therefore, Lcn2-mediated deprivation of iron could 
result in an inability to synthesize serotonin (Bachman et al., 2009). Additionally, Lcn2 
has the ability to reduce the bioavailability of catecholamines, as sequestration of iron 
occurs through binding available catechol groups (Bao et al., 2010; Miethke and Skerra, 
2010). In the brain, maintaining appropriate levels of catecholamines, which include 
norepinephrine and dopamine, is vitally important to behavioral homeostasis. In the DR, 
specifically, noradrenergic input from the locus coeruleus exerts tonic control on 5-HT 
neurons to increase serotonergic tone. (Baraban and Aghajanian, 1980, 1981; 
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Vandermaelen and Aghajanian, 1983; Pan et al., 1994). Therefore, our measured 
reduction of norepinephrine in the DR could be indicative of insufficient norepinephrine, 
which has been shown to result in reduced serotonergic neuron firing and less 5-HT 
release in target brain regions (Pudovkina et al., 2002). Inflammation-induced 
serotonergic hypofunction could be partly explained by the observed elevation in Lcn2, 
and consequent reduced TPH functioning and/or norepinephrine in the DR.  
Our findings of a 5-HT-mediated manic phenotype raise an important question: 
How can serotonergic hypofunction result in both manic and depressive-like behavior? 
Most reports of the association between neuroinflammation and neuropsychiatric disease 
have focused on the depressive aspects of disease, for example, “sickness behavior” 
following immune activation, or symptoms of depression in patients with rheumatoid 
arthritis, multiple sclerosis, or following IFNγ treatment. Furthermore, SSRIs, which 
increase 5-HT availability, treat symptoms of depression in many patients implicating 
reduced 5-HT as an aspect of their pathophysiology. However, substantial evidence also 
links the 5-HT system to manic behavior. 5-HT is known to regulate hedonic, aggressive, 
and risk-taking behavior, all aspects of human mania (Jones and Fernyhough, 2007; 
Chandler et al., 2009; Minassian et al., 2011; Haralanova et al., 2012). Interestingly, a 
recent study reported an association between immune activation and manic symptoms in 
patients with depressive disorders (Becking et al., 2013), helping to link the seemingly 
conflicting epidemiological evidence. Indeed, the prevalence of sub-threshold manic 
symptoms is ~40% in patients with unipolar depression (Zimmermann et al., 2009; Angst 
et al., 2010), suggesting that these disorders may be part of a spectrum with potentially 
overlapping etiology. 
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In summary, our findings demonstrate a profound ability for localized 
inflammation in the DR to induce manic-like symptoms, which were associated with 
neurotransmitter imbalance within the DR. These findings support the hypothesis that 
neuroinflammation may be a key etiological component in the development of mania, 
and further demonstrate that the DR is a critical brain region mediating these behavioral 
outcomes. These findings implicate dysregulation of serotonin signaling as important 
mediators of the effects of neuroinflammation on behavior. 
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FIGURES AND LEGENDS 
 
 
	  
Figure 4.1 IL-1β  overexpression within the DR causes local neuroinflammation. 
Location of the DR in the Mouse Brain Atlas (A) (Paxinos and Franklin, 2001). 
Representative images highlight spatially-restricted β-Gal (B) and GFP 
immunofluorescence (C) following AAV-Cre infusion. Insets (b’ and c’) represent 
higher magnification of subfield. AAV-Cre infusion significantly increases IL-1β mRNA 
in both males and females in the DR (D). Immunofluorescent characterization of 
microglia (E, CD11b) neurons (F, J NeuN), astrocytes (G, K GFAP, H, L AQP4) and 
indoleamine 2,3-dioxygenase (I, M IDO), an enzyme that catabolizes tryptophan in 
AAV-GFP infused mice (E-H) and AAV-Cre infused mice (I-L). Enzyme linked 
immunosorbant assay (ELISA) of plasma samples reveals no effect of DR AAV-Cre 
infusion on circulating IL-1β (N). Data are presented as mean ± SEM, N = 6-7; **, P < 
0.01 denotes main effect of treatment following two-way ANOVA comparing sex or 
genotype (WT vs. IL-1β) by treatment (AAV-GFP vs. AAV-Cre).  
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Figure 4.2 IL-1β-mediated neuroinflammation in the dorsal raphe causes manic-like 
behavior. In the elevated plus maze, both male (A-C) and female (D-F) IL-1βXAT mice 
infused with AAV-Cre display increased locomotion (A, D), time in the open arm (B, E), 
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and time in the distal ends of the open arm (C, F). In the light-dark box, both male (G-I) 
and female (J-L) IL-1β mice infused with AAV-Cre travel a greater distance in the light 
compartment (distance, normalized to time spent in light compartment) (G, J), transition 
more between light and dark compartments (H, K), and spend more time in the light 
compartment (I, L). In the locobox, male (P-S) IL-1β mice infused with AAV-Cre travel 
more throughout the test (M) at a greater speed (N), while transitioning fewer times 
between compartments (O) and having no significant preference for either compartment 
(P). Female (Q-T) mice showed a similar pattern as the males. Data are presented as 
mean ± SEM, N = 6-10; *, P < 0.05, **, P < 0.01 using within sex two-way ANOVA of 
genotype (WT vs. IL-1β) by treatment (AAV-GFP vs. AAV-Cre), followed by Tukey’s 
multiple comparison test. 
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Figure 4.3 IL-1β-mediated neuroinflammation in the dorsal raphe increases male 
stress responsivity. Male IL-1βXAT mice infused with AAV-Cre (A) display an increase 
in corticosterone production in response to a 15-min restraint stress (shaded), while 
exhibiting no difference in baseline or recovery. No significant effects were observed in 
females (B). Data are presented as mean ± SEM, N = 9-11, **, P < 0.001 using a within-
sex two-way rmANOVA comparing genotype (WT vs. IL-1β) vs. treatment (AAV-GFP 
vs. AAV-Cre), with time as a repeated measure. 
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Figure 4.4 Acute microinfusion of IL-1β  into the DR results in increased locomotion 
but no change in open arm exploration in the elevated plus maze. Male and female 
mice infused with IL-1β 30 min prior to testing on the elevated plus maze display 
increased locomotor activity (A), but no change in open arm exploration (B) or time 
spent in the distal arms (C). PFC neuroinflammation does not induce manic-like 
behavior or physiology. Male and female IL-1βXAT mice infused with AAV-Cre showed 
no difference in behavior on the elevated plus maze (D-F) or light-dark box (G, H). 
Neither males (I) nor females (J) display differences in corticosterone response to an 
acute 15 min restraint stress (shaded). Data are presented as mean ± SEM, N = 7-8. *, P < 
0.05 denotes main effect of infusion following a two-way ANOVA comparing sex vs. 
treatment (AAV-GFP vs. AAV-Cre). 
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Figure 4.5 IL-1β-mediated neuroinflammation in the dorsal raphe results in broad 
changes in gene expression. Heat map illustrating significant differences in gene 
expression between AAV-GFP and AAV-Cre infused male and female DR RNA (A), 
where data are expressed as relative levels within each gene, and both animals and genes 
are organized by hierarchical clustering. Genes that were either significantly up-regulated 
(B) or significantly down-regulated (C), as determined by an FDR of 0.01, are ranked by 
enrichment score and organized by functional gene clusters identified using the DAVID 
bioinformatics database. A separate analysis was performed on genes annotated with the 
gene ontology (GO) term “neur*,” which identified 26 genes that are down-regulated in 
IL-1β animals infused with AAV-Cre (D).	  
 
 
 
 
 
	  
	  
105	  
	  
Figure 4.6 IL-1β-mediated neuroinflammation in the DR results in serotonergic 
hypofunction. Immunofluorescence of TPH-immunoreactivity  (A, B) was used to 
identify serotonergic neurons (red), counterstained with the nuclear stain, DAPI (blue), of 
AAV-GFP (A) and AAV-Cre (B)-infused DR 8 weeks following AAV infusion (n=4). 
Quantification revealed fewer TPH-ir cells in AAV-Cre infused animsl (C). HPLC 
analysis of biogenic amines of the DR (D) less norepinephrine (E, NE) but no change in 
dopamine (F, DA). In the PFC (G), AAV-Cre infused animals had less serotonin (B, 5-
HT), increased levels of the metabolite (C, 5HIAA), and an overall increase in 
neurotransmitter turnover (D, 5HIAA/5-HT ratio). Data are presented as mean ± SEM, N 
= 6-7; **, P < 0.01, ***, P < 0.0001 following t-test comparing AAV-GFP and AAV-Cre 
infusion. 
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Figure 4.7 Acute increase in serotonin ameliorates manic-like phenotype in the 
elevated plus maze. IL-1β mice were infused with AAV-GFP or AAV-Cre into the DR 
and tested for three consecutive weeks on the elevated plus maze 32 minutes after i.p. 
injection with saline (tests 1 and 3) or 30mg/kg citalopram (test 2, shaded). Male IL-1β 
mice infused with AAV-Cre (A-C) show a significant attenuation of distance traveled 
(A), open arm time (B) and distal open arm entries (C) following citalopram treatment. 
Females (D-F) show a similar pattern of behavior. Data are presented as mean ± SEM, N 
= 4-5, *, P < 0.05, **, P < 0.01 following two-way ANOVA of treatment by trial. Post-
hoc test compared citalopram to saline treatments. 
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CHAPTER 5: GENERAL CONCLUSIONS AND FUTURE DIRECTIONS 
 
Neuropsychiatric diseases represent a major public health burden worldwide, and 
are the leading cause of disability in the United States. Treatments do exist for many of 
these diseases, yet gaps in the understanding of their causal mechanisms have left up to 
30% of patients refractory to treatment (Souery et al., 2006). In light of this lack of 
efficacy, it is necessary to identify common mechanism and risk factors for 
neuropsychiatric disorders. Fortunately, epidemiological observations have identified 
activation of inflammatory signaling cascades as a risk factor for and stress dysregulation 
as a concomitant symptom of a number of neuropsychiatric disorders. Therefore, the goal 
of this dissertation was to elucidate the role of neuroinflammation as a determinant of 
stress sensitivity and perhaps ultimately of disease. As there are major sex difference in 
incidence and presentation, this body of work also includes an investigation into how sex 
differences in the stress-responsive dorsal raphe nucleus (DR) may contribute to 
differences in vulnerability to neuropsychiatric disease. The hope is that a better 
understanding of the intersection of neuroinflammation and stress physiology, at a brain 
region-specific level of investigation, may provide the framework to develop more 
appropriate targets for individualized therapeutics. 
The work described in the previous chapters extends our knowledge of the 
contribution of both neuroinflammation and sex as representing specific vulnerabilities 
towards stress dysregulation. In Chapter 2 we utilized a genetic model of stress 
sensitivity to describe a role for inflammatory signaling pathways to regulate 
hypothalamic-pituitary-adrenal (HPA) stress axis function. In this model, the DR, and not 
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other stress responsive brain-areas, was identified as a locus of heightened responsivity. 
Chapter 3 furthered this investigation of the stress-sensitive DR by describing sex 
differences in response to the stress neuromodulator, corticotropin-releasing factor 
(CRF). Together, these findings support a unique role for the DR as a site of potential 
vulnerability towards neuropsychiatric disease, whereby differences in responsivity may 
influence susceptibility to stress related disorders. In Chapter 4, we probed a role for DR 
neuroinflammation to affect stress sensitivity, showing that neuroinflammation localized 
to this brain region results in dysregulated stress behavior and physiology through 
interactions with the serotonergic neurotransmitter system.  
Below I discuss the implications and important future directions supported by 
these studies, as well as the utility for using appropriate animal models to understand how 
vulnerabilities can impact stress behavior and physiology through discrete action in 
specific brain regions.  
 
Modeling stress dysregulation 
A variety of animal models have been developed to advance our understanding of 
the pathophysiology of stress-related disorders, with recent approaches emphasizing the 
modeling of symptoms, aspects, or endophenotypes, rather than specific disorders per se. 
Common approaches are the use of genetics, social and environmental manipulation, and 
pharmacology, each of which pose varying challenges with respect to construct, face, and 
predictive ability (Nestler and Hyman, 2010).  
Work presented in this thesis began with the utilization of a genetic model of 
stress sensitivity, the corticotropin-releasing factor receptor 2-null mouse (CRFr2-/-), to 
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test the hypothesis that inflammation plays a causal role in the dysregulated stress state. 
Numerous studies have previously examined the impact of different stressor paradigms 
on pro- and anti-inflammatory cytokines in the brain and periphery. However, reports 
have been conflicting; in some models stress drives increases in cytokine production, 
while other models demonstrate an immunosuppressive response. For example, Reyes 
and colleagues identified a number of immune-related genes that were upregulated in the 
paraventricular nucleus of the hypothalamus of mice in response to restraint stress (Reyes 
et al., 2003). Similarly, inflammatory cytokines were increased and anti-inflammatory 
cytokines were decreased after a 4-day chronic mild stress paradigm in male Wistar rats 
(You et al., 2011). In contrast, a longer chronic mild stress paradigm in mice actually 
reduced central IL-1β expression (Bartolomucci et al., 2003). The differences observed in 
these studies highlight the challenge of the extrapolation of results across methodologies 
and models. One explanation of these discrepancies is that specific characteristics of each 
stress exposure dictate the degree of neuroimmune responsivity, as does the particular 
brain region in which measurements occur. Additionally, the activation of astrocytes 
following chronic stress in CRFr2-/- and not WT mice suggest that stress sensitivity and 
genetic composition of the model are also important factors. Future investigation using 
other models of stress vulnerability would provide additional insight into which aspects 
of the neuroimmune response to stress are model-specific, and which may be more 
generalizable. These common and penetrant factors across many animal models are 
therefore most likely to translate from the bench to the bedside and offer targets for 
therapeutics of neuropsychiatric diseases in humans.  
Moving forward, there are many exciting areas of research that can be built upon 
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this recent work. For example, it is known that prenatal stress, a risk factor for stress-
related disorders, influences later life response to an inflammatory challenge, but whether 
it impacts the sensitivity of a neuroimmune response to stress exposure has not been 
determined. Further, long-term neuroimmune consequences of adolescent stress exposure 
would shine light on the applicability of these findings to specific human at-risk 
populations.  
 
Anti-inflammatory drugs in the treatment of psychiatric disorders 
In Chapter 2, we presented evidence that anti-inflammatory drugs might be 
beneficial for the treatment of stress-related mood disorders. Indeed, when this work was 
published, a number of clinical trials had just begun to test this very hypothesis. For 
example, acetyl-salicylic acid, anti-TNFα agents, and minocycline (an inhibitor of 
microglia) are all currently under investigation for efficacy as adjunct treatment for 
bipolar disorder, schizophrenia, and depression [reviewed in (Girgis et al., 2014)]. One 
such investigation has met with recent success in a subpopulation of treatment-resistant 
patients with major depressive disorder, those with elevated marks of inflammation 
(Raison et al., 2013). This double-blind, placebo-controlled clinical trial tested the 
efficacy of infliximab, a chimeric monoclonal antibody that binds to and inhibits the 
soluble and transmembrane form of TNFα. This trial revealed that infliximab–mediated 
inhibition of TNFα was able to reduce depressive symptoms specifically in those patients 
with an elevated baseline level of C reactive protein (>5 mg/L).  
Despite the success with the anti-TNFα treatment, other studies have shown 
minimal efficacy. This is likely due to the widespread and nonspecific effects on both the 
	  
	  
111	  
brain and immune system following systemic administration of these anti-inflammatory 
agents. This points to a clear clinical readout of the known heterogeneity in disease 
presentation, and importantly, suggests the potential for differences in disease etiology 
that may explain differences in treatment efficacy amongst individuals and populations. 
Moving forward, a more targeted approach is clearly necessary for both characterization 
of patient populations and specific effects of therapeutics. 
 
Focusing on anatomical loci of vulnerability 
Markers of neuroimmune activation, including changes in astrocyte activation, 
have been identified in patients with bipolar disorder (Rao et al., 2010) and depression 
(Shelton et al., 2011). This suggests that a relationship between stress-induced 
neuroimmune activation and neuropsychiatric disease may serve an important role as a 
biomarker of disease. Because astrocytes are widely heterogeneous in structure and 
function, and play distinct roles across different brain areas, astrocyte changes common 
across regions may be simultaneously causal to or resultant from disease-associated 
dysregulation. For example, changes within astrocytes found in the DR (e.g. ‘activation’) 
may be inductive of stress-sensitivity, but those same changes in the prefrontal cortex, 
while no doubt biologically important, may not be causal of stress-sensitivity due to 
differences in the functions of the two distinct brain regions. 
In Chapter 2 we identified this same kind of brain region specificity to the effects 
of stress exposure on neuroimmune activation. In these studies, the prefrontal cortex was 
a particularly susceptible brain region to stress, as measured by an increase in the 
astrocyte-specific protein, glial fibrillary associated protein (GFAP). These results fit 
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with our understanding of its role in assessing stressor controllability and interpretation of 
stressor intensity (Amat et al., 2005). However, in subsequent studies presented in 
Chapter 4, we found that overexpression of IL-1β within this brain region did not impact 
HPA axis responsivity. This suggests, as stated above, that chronic stress-mediated 
changes in neuroimmune markers in the PFC may be a secondary consequence to the loci 
of its impact on behavior. We also found that the ventral hippocampus, but not the dorsal 
hippocampus, was vulnerable to stress-induced neuroimmune activation. In addition to its 
role in memory formation and storage, the hippocampus plays a central role in the 
regulation of the HPA axis, and lesions to the hippocampus influence hormonal stress 
responsivity. It has been suggested that the dorsal and ventral hippocampus play 
functionally distinct roles in the regulation of stress and emotion, where the ventral 
hippocampus play a greater role in regulating HPA stress axis responsivity and negative 
feedback (Fanselow and Dong, 2010). 
To locate the primary area causal to these secondary region-specific effects, we 
performed a follow-up investigation within the DR, which has serotonergic outputs to 
both the affected areas, as well as throughout the brain. Previous work in the lab has 
shown that the DR is vulnerable to chronic stress-induced changes in neuronal survival 
and in electrophysiological properties of 5-HT neurons (McEuen et al., 2008). Cell death 
can result in the activation of astrocytes in target brain region, and both 5-HTergic 
dennervation and lesions to the DR have been shown to directly result in cytokine 
production and an upregulation of astrocytic expression of GFAP in DR projection sites 
(Frankfurt et al., 1991). Therefore, we hypothesized that differences in the stress 
responsivity of DR neurons may be an upstream mediator of the neuroinflammatory 
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response we observed in the prefrontal cortex and ventral hippocampus.  
This hypothesis was examined through cFos immunohistochemistry, a marker of 
neuronal activation, in the DR following exposure to an acute restraint stress. We 
predicted that neuronal activation in the DR would cause increased neuroimmune 
activation in these downstream regions. We surmised that a chronic over-activation of the 
DR neurons would increase the metabolic demand in the DR and its target areas, 
eventually leading to increased neuroimmune activation. In line with our prediction, we 
found that only the chronically stressed CRFr2-/- mice showed enhanced cFos, with levels 
twice that of any of the other groups. This, along with the neuroimmune activation 
presented in Chapter 2, was prevented in animals that had been given anti-inflammatory 
treatment throughout the course of their chronic stress exposure. This finding supports 
the DR as an upstream mediator of heightened stress responsivity, whose differences in 
response to a stressor may explain differences in behavior and physiology observed in the 
CRFr2-/- mice. 
Although we were able to determine the region specific to the observed stress-
sensitivity, cFos staining alone does not tell us which cell types comprise this increased 
activation. A major advancement to our understanding of this circuit would be the 
knowledge of which cell type – the most abundant of which are serotonergic, 
GABAergic, or glutamatergic – are differentially activated in response to the acute 
stressor. It is quite possible to explain the observed phenotype with activation of any one 
(or a combination) of these neuronal sub-types. One such possibility is that this over-
activation occurs in GABAergic interneurons, which would likely indicate increased 
inhibitory tone over the 5-HT neurons, reducing the 5-HT output to target regions, 
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consistent with the enhanced anxiety-like behavior previously reported in these mice 
following exposure to chronic stress (Bale et al., 2000; Bale and Vale, 2003; McEuen et 
al., 2008).  
 
Sex differences as a model of vulnerability 
To further probe the hypothesis that differences in DR responsivity underlie 
vulnerabilities in stress coping behavior and physiology, Chapter 3 sought to examine sex 
differences in the DR, with females representing a different vulnerable population. We 
hypothesized that some of the sex differences in stress responsivity and responses to drug 
treatment may also be found in this brain region. In fact, we found this to be the case, 
where males and females had divergent behavioral, physiological, and 
electrophysiological responses to DR-infused or bath applied CRF.  
The observed sex differences in electrophysiological response to bath applied 
CRF were particularly intriguing. Specifically, neurons from non-stressed and WT males 
showed an increase over baseline in IPSC rise time, half-width, and decay time in 
response to CRF, whereas female neurons showed the opposite responses. This suggests 
differences in their cellular adaptation to the stress neuropeptide. Interestingly, male mice 
that had previously undergone social defeat had responses more similar to females, rather 
than control males (Challis et al., 2013). It should be noted that the 5-HT neurons in 
which recordings were performed showed reduced average excitability compared to the 
neurons in the social defeat study. These differences may be attributed to the fact that all 
of our animals were individually housed, a context which is known to alter neuron 
excitability (Sanchez et al., 1995). 
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The findings from this work highlight the importance of identifying sex 
differences in central stress pathways. Females have an increased predisposition for 
developing disorders exacerbated by stress exposure; therefore identification of sex-
appropriate, and potentially sex-specific, pharmacological treatments is essential. 
 
Neuroinflammatory regulation of serotonin signaling 
5-HT within the brain acts through a diverse assortment of membrane-bound G-
protein coupled receptors and ligand-gated ion channels; to date, 14 subunits of the 5-HT 
receptor have been identified. Differences in their specific coupling create a diverse array 
of potential downstream signals. For example, activity through 5-HT1 receptors reduces 
cAMP, resulting in an inhibitory effect as measured by an increase in frequency and 
amplitude of IPSCs. 5-HT can also function as an excitatory neurotransmitter through 
activation of receptors coupled to Gs (5-HT4, 6, 7), Gq (5-HT2), or ligand-gated Na+/K+ 
cation channels (5-HT3). Therefore, identifying the serotonin receptor subtype in target 
regions is crucial in determining the mechanism by which it is mediating its effects on 
behaviors of interest. 
In Chapter 4 we presented data that support the hypothesis that the 5-HTergic DR 
is a locus of susceptibility to neuroinflammation. Specifically, there were marked 
behavioral changes that clearly link neuroimmune activation, neuropsychiatric disease, 
and the 5-HT system. In our studies, we described a 5-HT-mediated manic-like 
phenotype yet 5-HTergic hypofunction is more commonly associated with depressive-
like behavior. In fact, selective 5-HT reuptake inhibitors  (SSRIs), which increase 5-HT 
availability by blocking transporter reuptake, treat symptoms in a large percentage of 
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depressed patients, implicating reduced 5-HT as an aspect of depression’s 
pathophysiology. Moreover, neuroinflammation has also been linked to depressive 
aspects of disease. For example, there have been multiple observations of “sickness 
behavior” following immune activation, or symptoms of depression in patients with 
rheumatoid arthritis, multiple sclerosis, multiple sclerosis, or following IFNγ treatment.  
Despite these associations with depression, substantial evidence also links the 5-
HT system to manic behavior. 5-HT is known to regulate hedonic, aggressive, and risk-
taking behavior, all aspects of human mania (Ramrakha et al., 2000; Watson et al., 2004; 
Jones and Fernyhough, 2007; Chandler et al., 2009; Minassian et al., 2011; Haralanova et 
al., 2012). Furthermore, lesions to the DR have been shown to increase exploration in the 
open arm of the elevated plus maze (Briley et al., 1990). Interestingly, a recent report has 
found an association between immune activation and manic symptoms in patients with a 
depressive disorder (Becking et al., 2013), perhaps helping to link the seemingly 
conflicting evidence of 5-HT mediating both manic and depressive behavioral 
phenotypes. Indeed, the prevalence of sub-threshold manic symptoms is ~40% in patients 
with unipolar depression (Zimmermann et al., 2009; Angst et al., 2010), suggesting that 
these disorders may be part of a spectrum with potentially overlapping etiology. 
IL-1β is known to affect 5-HT synthesis and release. When administered into the 
hypothalamus, IL-1β augments 5-HT release (Shintani et al., 1993), and direct 
administration of the cytokine into the DR has been shown to result in reduced 
spontaneous 5-HTergic neuron firing (Manfridi et al., 2003). However, the link between 
elevated IL-β and changes to 5-HTergic neurons in the context of behavior remains to be 
fully explored. We identified numerous changes evoked by our neuroinflammatory 
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stimulus on the structure and function of the DR that could explain this connection, 
although further investigation is certainly warranted. In an analysis of gene expression 
changes, we identified lipocalin-2 (Lcn2) based on its basal sex difference in expression 
(F>M), and because it presented with one of the greatest fold-change increases following 
DR inflammation. Lcn2, an iron-binding sideophore, is commonly increased in response 
to inflammatory insult due to its ability to deprive bacteria of necessary iron. Thus, it 
serves an important protective role in the case of bacterial infiltration.  
Despite its normally protective role, Lcn2 upregulation may also have substantial 
deleterious effects. First, it likely serves to deprive brain cells of iron (Bachman et al., 
2009). Importantly, tryptophan hydroxylase (TPH), the rate-limiting enzyme in the 
synthesis of serotonin, requires ferrous iron (Fe2+) for proper enzymatic activity (Nakata 
and Fujisawa, 1982a, b). Therefore, the deprivation of this ion could result in an inability 
to synthesize 5-HT. Second it could reduce the bioavailability of catecholamines, as Lcn2 
sequesters iron by binding to available catechol groups (Bao et al., 2010; Miethke and 
Skerra, 2010). In the brain, maintaining appropriate levels of catecholamines, which 
include norepinephrine and dopamine, is vitally important to behavioral homeostasis. In 
the DR noradrenergic input from the locus coeruleus exerts tonic control on 5-HT 
neurons to increase 5-HTergic tone (Baraban and Aghajanian, 1980, 1981; Vandermaelen 
and Aghajanian, 1983; Pan et al., 1994). The absence of sufficient norepinephrine results 
in reduced 5-HTergic neuron firing and less 5-HT release in target brain regions 
(Pudovkina et al., 2002). Therefore, inflammation-induced 5-HTergic hypofunction could 
be partly explained by the observed elevation in Lcn2, and consequent reduced TPH 
functioning and/or norepinephrine in the DR.  
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To address this theory, it would be important to perform a direct measure of iron 
in both its oxidized and reduced state. Additionally, this hypothesis would be greatly 
strengthened by overexpressing Lcn2 directly into the DR, or, alternatively, by 
performing these experiments in a mouse with a conditional deletion of Lcn2 in the DR. 
Interestingly, global Lcn2-deficint mice have recently been shown to have increased 
stress-induced anxiety-like behavior, cognitive impairments in spatial learning tasks, and 
hyperactivation of the HPA axis, supportive of a role for this protein in stress related 
behavior and physiology (Ferreira et al., 2013). However, due to the lack of brain region 
specificity in these experiments, which were performed on whole body knockout mice, 
further investigation is warranted to better understand the mechanism by which Lcn2 
mediates these observed phenotypes. Nonetheless, the evidence that altered Lcn2 can 
impact stress-related behaviors are of great relevance.  
 
General implications 
The work presented in this thesis has shown that hyper- or hypo-function of the 
dorsal raphe nucleus, based on genetic susceptibility, sex, or inflammatory insult, can 
result in manic- and depressive-like behavior. The novelty of these findings centers on 
the importance of the loci impacted by these differences. The dorsal raphe nucleus has 
previously been identified as a vulnerable region to impact stress coping and physiology; 
here we demonstrate the specific, mechanistic link between risk factors for stress-related 
disorders, and quantitative changes to this brain region and its functional output.  
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INTRODUCTION 
Mood and anxiety disorders are more than twice as common in women than men. 
As stressful life experiences are known triggers for disease onset, disease prevalence in 
females may be explained by the well-established sex differences in stress sensitivity 
(Handa et al., 1994; Goel and Bale, 2009). This sex bias is associated with differences in 
corticotropin-releasing factor (CRF) neurotransmission, and sex differences have been 
identified in expression and signaling of both CRF receptor subtypes, CRFr1 and CRFr2. 
This stress-sensitive signaling cascade is susceptible to perturbations from the 
environment, including neuroinflammatory stimuli. Interestingly, CRFr2 is located both 
in the brain and on immune organs and circulating immune cells, where it plays a pivotal 
role in regulating both stress and immune responsivity. Importantly, there are known sex 
differences in the immune response of males and females, including a difference in 
susceptibility to neuroinflammation (Schuurs and Verheul, 1990; Xiao et al., 2012).  
Toxoplasma (T.) gondii is an intracellular obligate parasite with the ability to 
cross the blood-brain-barrier and induce neuroinflammation. In the chronic stage of 
infection, neuroinflammation is maintained while peripheral infection is cleared. As such, 
T. gondii infection is a powerful tool to test the hypothesis that neuroinflammation is 
responsible for sex-specific differences in the neurocircuitry and behaviors associated 
with stress dysregulation. Furthermore, exposure to T. gondii in utero has been linked 
with increased risk for the development of sex-biased neuropsychiatric disorder, making 
T. gondii an etiologically relevant source of neuroinflammation (Henriquez et al., 2009; 
Arias et al., 2011).  
The current studies sought to determine the sex-specific impact of T. gondii-
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induced neuroinflammation on stress related behavior in male and female mice. As 
CRFr2 plays an important role in regulating both stress and immune responsivity, we also 
sought to determine whether T. gondii-induced stresss dysregultion is mediated through 
CRFr2. To test this hypothesis, male and female mice were chronically infected with T. 
gondii and assessed for changes in anxiety-like behavior, glucocorticoid production, 
weight change, and survival. In a parallel study, males and females were sacrificed during 
acute or chronic infection, and brains were harvested for gene expression analysis and 
serum collected for cytokine analysis.  
 
METHODS 
Animals 
Mice were generated in-house from CRFr2 heterozygrous breeding pairs on a mixed 
C57Bl/6:129 background to yield WT and CRFr2-/- littermates. Same-sex littermates (14-
16 weeks) were housed in groups of 3-5 under a 12h L/D cycle, with food and water 
available ad libitum.  
 
Assessment of weight and survival 
Body weight was measured weekly, beginning one week prior to infection with T. gondii, 
at approximately 1400 h throughout the study. Mice were monitored daily for health and 
survival status. 
 
Toxoplasma gondii infection 
Me49 cysts were harvested from the brains of chronically infected CBA/J mice. Brains 
	  
	  
122	  
from infected mice were homogenized in sterile DPBS and an aliquot was used to count 
cysts. The suspension was diluted in DBPS pH7.4 and experimental animals were 
injected i.p. with 20 cysts. Naïve animals were injected with sterile DPBS alone to 
control for the stress exposure of injection. 
 
HPA assessment 
Plasma corticosterone levels were determined following a 15-min restraint stress in male 
WT and CRF2-/- mice (N = 7-9 per genotype/treatment group). Testing was administered 
between 0800–1100 h on the final day of CVS by placing mice in a 50 ml conical tube 
containing a 50 mm air hole. Tail blood samples (10 µL) were taken at onset and 
completion of restraint (0 and 15 min, respectively). To examine the stress recovery 
phase, additional samples were collected at 15 min and 75 min following the culmination 
of restraint (30 and 90 min, respectively). Samples were collected into 5 µL of 50 mM 
EDTA, centrifuged, and stored at -80°C until the assay was performed. Plasma 
corticosterone concentration was measured in duplicate using a 125I-corticosterone 
radioimmunoassay kit (MP Biomedicals, Orangeburg, NY). The minimum detection limit 
of the assay was 7.7 ng/ml and intra-assay coefficient of variation was 7.3%.  
 
Elevated plus maze 
Adult mice (n = 7-10 per group) were placed in the center square of the maze facing the 
open arm at the beginning of the 5 min test. Light intensity in the open arms was 300 lux. 
Testing occurred 2-5 h after lights on. Testing was digitally recorded and distance and 
time spent in each arm were analyzed automatically using ANY-maze v4.75 software 
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(Stoetling Co., Wood Dale, IL). 
 
Brain gene expression  
Whole brains were cryosectioned at -20°C. Using a hollow needle (Ted Pella Inc., 
Redding, CA), brain regions were micropunched according to the Paxinos and Franklin 
atlas (Paxinos and Franklin, 2001) and the ventromedial hypothalamus was collected. 
Punches were probe-sonicated for 2.5 min (30 sec on/off cycles) in TRIzol reagent 
(Invitrogen, Carlsbad, CA). RNA was isolated by chloroform extraction, as previously 
described (Howerton et al., 2013). cDNA was transcribed, and quantitative gene 
expression of CRFr2 was determined through TaqMan gene expression assay according 
to the manufacturer’s instructions (Invitrogen). 
 
Cytokine Luminex assay 
A mouse 20-plex antibody bead kit (BioSource, Cmarillo, CA) was used to measure the 
level of 20 cytokines and chemokines in 50 µL of serum from naïve, acutely infected 
(10d post infection) or chronically infected (28d post infection) mice. Analytes included 
cytokines: IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-15, IL-17, 
TNF-α, IFN-α, IFN-γ, and granulocyte-macrophage colony-stimulating factor (GM-
CSF); cytokine receptors: IL-1Rα and IL-2R (CD25); and chemokines: eotaxin (CCL11), 
IFN-γ-inducible protein (IP-10, CXCL10), Mig (CXCL9), and MCP-1 (CCL2). Data 
were collected using a Luminex-100 array reader (Luminex Corp., Austin, TX). 
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Statistics 
An investigator blind to animal treatment group conducted all studies and analyses. EPM 
box measures were analyzed within sex by t-test. Gene expression analysis was analyzed 
by two-way ANOVA. Weekly measures of weight change were analyzed within-sex 
using a repeated-measures ANOVA with genotype and infection as the independent 
variables, and time as a within-subject repeated measure. Plasma corticosterone was 
analyzed within-sex using a two-way ANOVA for genotype and infection, with time as a 
within-subject repeated measure. Gene expression was analyzed by t-test comparing 
naïve and chronically infected male mice. Cytokines were analyzed both by expression 
level, and as a binomial analysis as to whether the cytokine was detected in a given 
sample. Significant differences were identified at p ≤ 0.05. All statistics above were 
performed using JMP8 (SAS) software, and all data are reported as mean ± standard error 
of the mean (SEM).   
	  
RESULTS 
Deficiency in CRFr2 rescues female mortality following T. gondii infection 
To study sex differences in susceptibility to T. gondii infection, age-matched WT and 
CRFr2-/- male and female littermates, all on a C57:129 mixed background, were infected 
i.p. with T. gondii (Fig. A.1). Upon infection with 20 cysts of the type II Me49 strain, WT 
male mice survived at a rate of 91% and females were susceptible with a survival rate of 
9%. This susceptibility was rescued in CRFr2-/- mice, where CRFr2-/- of both sexes 
showed enhanced survival; 100% of CRFr2-/- male mice survived and 76% of female 
CRFr2-/- survived 65 days after IP infection. Fig. A.2 demonstrates time course of 
susceptibility to infection, which occurred in the chronic stage. 
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Deficiency in CRFr2 rescues attenuates weight loss following T. gondii infection 
Infection with T. gondii resulted in weight loss in all animals during the acute stage of 
infection (Fig. A.1). This weight loss was most dramatic in WT females, who were 
unable to regain weight in the chronic stage of infection. By the chronic stage of infection 
(Fig. A.2), CRFr2-/- mice regain substantially greater weight. 
 
Infection with T. gondii increases CRFr2 expression in the ventromedial hypothalamus 
CRFr2 plays an important role in feeding behavior via its effects within the ventromedial 
hypothalamus. Since CRFr2-/- female mice failed to show the same degree of weight loss 
as WT females, we sought to test the hypothesis that T. gondii infection increases CRFr2 
expression in this brain region. Infected animals showed significantly increased 
expression of CRFr2 in the ventromedial hypothalamus compared to naïve animals (t(1,8) 
= 2.621, p = 0.0306) (Fig. A.3).  
 
Deficiency in CRFr2 protects against T. gondii-induced heightened stress sensitivity  
T. gondii infection increased corticosterone production in response to an acute restraint 
stress (Fig. A.4) in WT male (F(1,36) = 9.024, p = 0.0048) and female mice (F(1,20) = 24.47, 
p < 0.0001). Infection had no impact on stress-induced corticosterone production in male 
(F(1, 24) = 0.9327, p = 0.344) or female (F(1, 20) = 0.6717, p = 0.422) CRFr2-/- mice. 
 
Deficiency in CRFr2 protects against behavioral changes in females infected with T. 
gondii 
The elevated plus maze provokes a stress response, whereby more stress-responsive 
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animals spend increased time in the closed areas. In both males and females was a 
significant main effect of genotype (F(3,27) = 19.66, p < 0.0001) and infection state (F(1,27) 
= 14.64, p = 0.0007), and an interaction (F(3,27) = 9.269, p < 0.0002) to increase time spent 
in the open arm of the elevated plus maze (Fig. A.6), illustrating that the behavioral 
effects of infection were specific to WT mice, and time spent in the open arm and distal 
ends of the open arm was attenuated in CRFr2-/- mice. 
 
Sex differences in cytokine expression  
Sex differences in expression levels and probability of expressing a cytokine were 
compared between WT and CRFr2-/- male and female mice from naïve, acutely infected, 
and chronically infected cohorts. A 3-way ANOVA was used to compare statistical 
differences in expression levels by genotype, sex, and treatment group. This analysis 
revealed differences including effects on genotype and/or sex in IL-1β (genotype x sex 
interaction, p = 0.0304), IL-4 (genotype, p = 0.0066, genotype x sex, p = 0.019, genotype 
x treatment, p = 0.0212), IL-6 (genotype, p = 0.0186), IL-12 (sex, p = 0.0105, sex x 
treatment, p < 0.001), MCP1 (sex, p = 0.0494, sex x treatment, p = 0.0108), MIG (sex x 
treatment, p = 0.0059, sex x genotype x treatment, p = 0.0112), TNFa (gentoype, p = 
0.0008, genotype x treatment, p < 0.0001, sex x treatment, p = 0.0003), and VEGF (sex, p 
< 0.0001, sex x treatment, p = 0.0197). When WT mice were looked at separately (Fig. 
A. 7), KC, IL-2, and VEGF displayed sex differences in probability of expression at all 
three time points - basally, during the acute stage of infection, and during the chronic 
stage of infection. IP-10 and MCP1 displayed sex differences in naïve animals, IL-12 
displayed sex differences in chronically infected animals, and IL-10, IL-4, and TNFa 
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displayed sex differences both in naïve and chronically infected animals.  
 
DISCUSSION 
 Sexual dimorphism in the immune system has been widely reported across 
species, including humans (Schuurs and Verheul, 1990; Nava-Castro et al., 2012; Xiao et 
al., 2012). With few exceptions, females are more susceptible to inflammatory conditions 
including asthma, multiple sclerosis, Sjogren’s syndrome, systemic lupus erythrematosus, 
rheumatoid arthritis, and polymyalgia rheumatica (Melgert et al., 2005; Tiniakou et al., 
2013). Inflammation is a known risk factor for the development of neuropsychiatric 
disorders, including depression, schizophrenia, and bipolar disease, which display sex 
differences in incidence, presentation, and trajectory of disease. The impact of 
inflammation on the development of these diseases may occur through its ability to 
influence an organism’s vulnerability to stress exposure.   
CRFr2 is located both in the brain and also on immune organs and circulating 
immune cells, where it plays a pivotal role in regulating both stress and immune 
responsivity (Baigent and Lowry, 2000). Therefore, the current studies sought to 
understand the role of CRFr2 in the susceptibility of females to inflammation-mediated 
changes in stress related behavior and physiology. T. gondii, which is among the natural 
infections for which females are more vulnerable, was used as a sledgehammer approach 
to induce neuroinflammation in male and female CRFr2-/- mice.  
As predicted, we found females to be more susceptible to the effects of T. gondii 
on survival and weight loss. Females displayed enhanced mortality, as has been reported 
in other strains of mice exposed to T. gondii. Females also lost more weight following 
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infection, an effect that was absent in CRFr2-/- mice. As the susceptibility to T. gondii 
was observed well into the chronic stage of infection, it is likely that these effects are 
driven by central expression of CRFr2. 
We also observed a substantial sex-specific behavioral effect of T. gondii 
infection in the elevated plus maze, and on glucocorticoid production in response to an 
acute stress exposure. Behavioral consequences of T. gondii infection have been 
previously reported, primarily in the context of disinhibition towards predator odor. Our 
findings suggest that this may be more applicable to stress-related behaviors in general. 
CRFr2-/- mice, however, displayed attenuated stress-induced glucocorticoid production, 
and attenuated behavioral changes in the elevated plus maze, suggesting a specific role 
for this receptor in modulating the interaction between inflammation and stress related 
behaviors in a sex-specific manner. The brain region specificity of these effects remains 
to be examined. 
Centrally, CRFr2 densely populate the ventromedial hypothalamus (VMH), where 
their activation results in enhanced signaling of excitatory projects to POMC neurons of 
the arcuate nucleus to inhibit feeding behavior (Poulin et al., 2012). Deficiency of CRFr2 
in this brain region leads to a disinhibition of this circuit, resulting in enhanced food 
intake (Chao et al., 2012). Therefore, it is possible that an inflammation-mediated 
increase in activation of CRFr2 in the VMH leads to enhanced weight loss observed in 
WT mice following infection with T. gondii. In CRFr2-/- mice, this inflammation-induced 
weight loss is abrogated by a lack of VMH activation of this circuit. To test this 
hypothesis directly, we would need to perform a site-directed knockdown of CRFr2 in 
this brain region prior to T. gondii infection, however, our findings that CRFr2 expression 
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is increased following infection is supportive of this hypothesis. 
To investigate the underlying cause of this susceptibility, male and female mice of 
both genotypes were euthanized either naively, or 10 days (acute) or 28 days (chronic) 
following infection. Serum was collected for the analysis of cytokines and chemokines 
that may be differentially regulated during these different stages in males and females. 
We detected a subset of these molecules that displayed sex differences across different 
time points, suggesting an additional peripheral immune response difference between 
males and females that may underlie their difference in susceptibility. 
In summary, CRFr2 appears to function as an important modulator of the 
interaction of the sex-specific effects of inflammation on stress responsivity. Our data 
indicate that CRFr2 may play a previously unappreciated role in signaling immune-brain 
interactions that mediate female stress sensitivity in neuropsychiatric disease.  
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FIGURES AND LEGENDS 
	  
Figure A.1 Deficiency in CRFr2 resuces female susceptibility to infection with T. gondii. 
Females are more susceptible to infection with T. gondii. Deficiency in CRF receptor-2 
rescues fatality of T. gondii infection, resulting in no deaths amongst males, and significantly 
fewer deaths amongst females. 
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Figure A.2 Survival curve of male and female mice following infection with T. gondii. 
Mortality following infection with T. gondii occurs in the chronic stage of infection (>28 dpi), 
and is specific to WT mice. WT female mice are the most susceptible group.  
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Figure A.3 CRFr2 deficiency attenuates weight loss following T. gondii infection. Both 
males and females lost weight following infection with T. gondii. Females are the most 
susceptible, losing up to 20% of their body weight and failing to re-gain weight. Both male 
and female CRFr2-/- mice are less susceptible to the weight affects of T. gondii infection.  
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Figure A.4 Infection with T. gondii increases expression of CRFr2 in the 
ventromedial hypothalamus of WT mice. Gene expression of CRFr2 within the 
ventromedial hypothalamus was compared from naïve or chronically infected male mice. 
Data are presented as mean values ± SEM (n=4-6). *, P < 0.05 following t-test. 
 
	  
	  
	  
	  
Naive Infected
0.0
0.5
1.0
1.5
2.0
2.5
3.0
C
R
Fr
2 
Fo
ld
 C
ha
ng
e 
(R
el
at
iv
e 
to
 N
ai
ve
)
*
	  
	  
134	  
	  
Figure A.5 CRFr2 deficiency rescues T. gondii-mediated heightened corticosterone 
response to an acute restraint stress. Both male and female WT mice display enhanced 
corticosterone production following an acute restraint stress (shaded bar) when infected with 
T. gondii. CRFr2-/- mice show no difference in stress responsivity following infection. Data 
are presented as mean values ± SEM (n = 4-7). 
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Figure A.6 CRFr2-/- mice are rescued from female-specific behavioral effects of 
infection with T. gondii. WT females spend more time in the open arms of the elevated plus 
maze.  
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Figure A.7 Sex differences in basal and T. gonii-induced cytokine and chemokine 
production. Venn diagram of sexually dimorphic cytokine and chemokines in naïve, 
acutely infected, and chronically infected males and females. Proteins listed are those 
with significantly different probabilities of expression between the sexes at each time 
point. Notably, VEGF, IL-2, and KC (keratinocyte chemoattractant) display sex 
differences in probability of expression at all three time points.  
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